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ABSTRACT
IMPACT OF EPIGALLOCATECHIN-3-GALLATE (EGCG), A BROAD-SPECTRUM
ANTI-INFLAMMATORY, IN CONTROLLING INTESTINAL FACTORS
CONTRIBUTING TO INFLAMMATORY BOWEL DISEASE
Gerald Wayne Dryden
February 8, 2016
This dissertation explores the role of epigallocatechin-3-gallate (EGCG), as a
potential treatment for patients with inflammatory bowel disease (IBD).
common disorder that causes a great deal of suffering.

IBD is a

Our understanding of the

etiologies, pathogenic mechanisms, and treatment targets continues to evolve. Many new
therapeutic targets are making their way through the pharmaceutical pipelines. However,
not all patients benefit from these therapies.
EGCG has long been studied as an anti-cancer agent. Most of our understanding
of this compound comes from the oncologic literature. As the pathways of oncology and
inflammation converge, new lessons can be taken from the cross discipline. EGCG’s
effects on intracellular signaling bridges cancer to inflammation. Many of the same
cytokines, chemokines, and molecular signals influencing cancer cells to grow also
stimulate immune cells. Chapter 3 first explores the role of EGCG as both a preventative
as well as a therapeutic agent and its effect on the dextran sulfate sodium (DSS) mouse
model of colitis. The influence of EGCG on immune cell function is then explored in
chapter 4. One novel approach in chapter 4 has to do with a focus on intestinal epithelial
cells as agents of an immune response, and how EGCG impacts their function in that
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role. Chapter 5 explores the impact of EGCG on bolstering barrier function, as this is an
important aspect of inflammatory bowel disease that is often neglected when considering
new approaches to treating IBD. Finally, chapter 6 ends this dissertation with the first
clinical trial in the world’s literature to evaluate EGCG as a therapeutic for IBD.
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CHAPTER 1
INTRODUCTION
1.1

BACKGROUND

INFORMATION

ON

IBD

AND

GREEN

TEA

POLYPHENOLS

1.1.1

IBD EPIDEMIOLOGY AND SYMPTOMATOLGY
Inflammatory Bowel Disease (IBD) is a common chronic inflammatory process

involving the digestive tract. IBD affects up to 1.5 million individuals in the US alone.
The classification of IBD is generally divided into two main subgroups, Crohn’s disease
and ulcerative colitis (figure 1). A smaller category, indeterminate colitis, makes up
about 10-15% of all IBD cases. The clinical presentations of each group vary greatly,
and are, in part, determined by the pathophysiology of each disease state. Ulcerative
colitis is limited to the colon, where it affects a variable portion of the colon from the
rectum alone (proctitis) to disease involving the entire colon (pancolitis).

Crohn’s

disease, on the other hand, may affect the
IBD: 1.5 million patients

Crohn’s
disease

Ulcerative
colitis

Indeterminate
colitis (15-20%)

Figure 1. Nomenclature of IBD

digestive tract anywhere from the mouth to the
anus. The most common site of involvement is
the terminal ileum, which may be affected in up to
90% of cases.

The colon is less commonly

involved, and up to 40% may have both the colon
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and small bowel involved.

Diarrhea, abdominal pain, and rectal bleeding are hallmarks of IBD (Bernstein,
Fried et al. 2010). Crohn’s disease is usually accompanied by right lower quadrant
abdominal pain, due to the high likelihood of ileal involvement (Silverberg, Satsangi et
al. 2005). Ulcerative colitis more commonly presents with left lower abdominal cramps,
urgency and tenesmus, as the rectum is universally involved. Both disease processes are
often accompanied by diarrhea, but ulcerative colitis more commonly exhibits rectal
bleeding due to the distal nature of its location and generalized involvement of the
mucosa. Ulcerative colitis tends to be a superficial inflammatory process involving the
epithelial lining (mucosa) and the adjacent submucosal tissue (Bernstein, Fried et al.
2010). In contrast, Crohn’s disease begins at the mucosa, but the distinct ulcerations may
penetrate deeply into the bowel wall, eventually leading to significant ulceration and even
perforation of the bowel. The tendency of Crohn’s disease to penetrate the bowel deeply
predisposes patients to form abscesses, fistulas, and strictures (Bernstein, Fried et al.
2010).

1.1.2 PATHOGENESIS OF IBD
Both disease processes result from a convergence of three factors: 1. Genetic
predisposition, 2. Environmental factors, and 3. Immune system abnormalities. Over
200 genes have been identified in genome-wide association studies (GWAS) of IBD
patients and their relatives, with many of them encoding abnormalities of genes involved
in innate and adaptive immunity (de Lange and Barrett 2015).
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The penetrance of

identified mutations varies greatly. The first described mutation associated with IBD, the
NOD-2 mutation, dramatically increases the risk of IBD (Hugot, Chamaillard et al. 2001,
Ogura, Bonen et al. 2001). While the presence of a mutation is not sufficient for the
development of IBD, a double dose of the mutation elevates the risk of disease by 20-40
fold (Cuthbert, Fisher et al. 2002). Evidence from animal studies demonstrates that
bacteria must be present in the lumen before inflammation can develop (Taurog,
Richardson et al. 1994). Genetically susceptible, but germ-free, animals have underdeveloped immune systems (Taurog, Richardson et al. 1994). Upon exposure to different
bacteria or bacterial products, inflammation develops in the GI tract with varying
intensity (Rath, Herfarth et al. 1996). Of course, humans cannot be raised under germfree conditions, but the composition of bacteria present in the microbiome may influence
the development of IBD (Fabia, Ar’Rajab et al. 1993, Swidsinski, Ladhoff et al. 2002,
Seksik, Rigottier-Gois et al. 2003).

Patients with IBD often experience a “trigger” that initiates their bowel
inflammation. A trigger might consist of the use of non-steroidal anti-inflammatory
medications, which may disrupt the epithelium and expose the underlying submucosal
immune system to higher levels of bacterial exposure, or the development of an enteric
infection, that initiates more than a self-limited inflammatory event.

1.1.3 INTERPLAY OF BACTERIA AND INTESTINAL BARRIER FUNCTION
A common estimate of the total number of human cells in a body approached 1 x
1012, while the human intestine contains up to 3 x 1013 bacterial organisms plus an
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undetermined number of discovered, as well as, uncharacterized viruses and fungi
(Sender, Fuchs et al. 2016). It has been stated that intestinal bacteria outnumber human
cells by a factor of 10:1, but this estimate has been recently revised to show that human
cells equal the number of bacterial cells at steady state, and assume superiority
temporarily after each defecation activity (Sender, Fuchs et al. 2016). Regardless of the
ratio of human to bacteria, a huge number of organisms in a complex mixture resides in
close proximity to the gastrointestinal immune system. The primary defense against
bacterial invasion is a physical barrier that depends on the integrity of the epithelial
border, consisting of a single layer of intestinal epithelial cells (IECs) buttressed by a
variety of secreted substances that augment its barrier function that is spread over 200 m2
of total surface area (Neish 2002). Specialized epithelial cells such as Paneth cells,
enteroendocrine cells and goblet cells secrete anti-bacterial peptides, immunoglobulins,
and mucins, respectively, that form a multi-functional coating that insulates the mucosa
from direct contact with the luminal compartment (Peterson and Artis 2014). The
secretion of mucins into the lumen forms a relatively impenetrable barricade separating
the acquired microbial population from the host epithelial cells. Mucin-2 (Muc2) is the
most abundant mucin secreted into the lumen (Johansson, Phillipson et al. 2008). The
absence of mucin in experimental models is associated with inflammation and even
colonic neoplasia in animal models deficient for Muc2 gene (Van der Sluis, De Koning et
al. 2006, Dharmani, Leung et al. 2011).

Additional contributors to mucin layer

stabilization include IEC secretion of trefoil factor 3 and resistin-like molecule (RELM)β that help maintain appropriate mucin content and structural integrity (Taupin and
Podolsky 2003, Herbert, Yang et al. 2009). Underneath the mucin layer lies a unique
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feature called the unstirred water layer. This thin aqueous environment is usually sterile
due to the effects of secreted anti-microbial peptides such as cryptidins, cathelicidins,
lysozyme, and REGIIIγ (Kim and Ho 2010, Gallo and Hooper 2012, Peterson and Artis
2014). Additionally, large amounts of immunoglobulins (Ig)G and secretory (s)IgA are
transferred across the epithelial border into the unstirred water layer, eventually diffusing
into the mucin layer. Genetic defects leading to impaired intracellular bacterial sensing,
Paneth cell and enteroendocrine cell dysfunction, and mechanisms involved in autophagy
and the unfolded protein response, are associated with an increased risk of IBD (Kaser
and Blumberg 2011).

A mutation in the gene encoding the intracellular protein

responsible for sensing muramyl dipeptide (MDP) (Kanneganti, Lamkanfi et al. 2007),
NOD2, was the first described genetic defect associated with Crohn’s disease
susceptibility (Cho 2001, Hugot, Chamaillard et al. 2001). This sensing protein has now
been implicated in a number of mucosal defense and tolerance functions, including
negative regulation of TLR stimulation (Watanabe, Kitani et al. 2004), upregulation of
tolerance inducing IL-10 (Noguchi, Homma et al. 2009), and Paneth cell regulation of
antimicrobial peptides such as α-defensin (Kobayashi, Chamaillard et al. 2005,
Wehkamp, Salzman et al. 2005).

NOD2 also functions as a key regulator for

coordinating the activities involved in autophagy (Kaser, Lee et al. 2008). First, the
binding of MDP to NOD2 actuates the formation of autophagic vesicles in enterocytes
and dendritic cells. Reduced or aberrant expression of NOD2, on the other hand, results
in impaired pathogen clearance (Cooney, Baker et al. 2010, Travassos, Carneiro et al.
2010). Second, the direct association of NOD2 with the normal autophagy protein
ATG16L1 initiates the autophagy machinery through intracellular recruitment of
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ATG16L1 to sites of bacterial invasion (Travassos, Carneiro et al. 2010). However, the
presence of a human ATG16L1 variant, T300A, impairs activation of autophagy, as seen
when the mutant gene was introduced into a murine model of autophagy (Lassen, Kuballa
et al. 2014). With the similarities between the animal model and the human condition,
the T300A mutation gains credibility as a mutation linked to Crohn’s disease
susceptibility, through its effect of blunting an adequate mucosal response in the face of
appropriate inflammatory stimuli (Cooney, Baker et al. 2010). This crossover between
intracellular pathogen sensing and activation of the autophagic pathway, which provides
important input into the manner by which immune activation should proceed in response
to commensals (immune tolerance), helps explain the seeming paradox whereby impaired
bacterial sensing can lead to an inappropriately aggressive immune response to nonpathogenic resident microflora (Kaser and Blumberg 2011). Times of stress, such as
during an intestinal infection, and other challenges to intracellular processing of bacterial
products, also trigger other cellular protection processes, such as the unfolded protein
response, which has also been linked to IBD (Kaser, Lee et al. 2008).

Intriguingly, optimal barrier function actually depends on the presence of bacteria.
The total bacterial population, or microbiome, residing in the lumen of the
gastrointestinal tract adds a considerable quantity of metabolic capacity to the human
physiology. Most bacteria exist as non-virulent commensal organisms. Resident bacteria
provide beneficial energy substrates obtained from complex carbohydrates that resist
human digestion, in the form of short chain fatty acids. These compounds support
important aspects of IEC function (Hamer, Jonkers et al. 2008). In addition, luminal
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bacteria supply nutrients required for normal human function, such as vitamin K.
However, the close proximity of such a large number of potential pathogens requires the
presence of a ready defense in the form of the lamina propria immune system, which
creates an immunological barrier to augment the physical barrier of the IECs.

1.1.4 ROLE OF THE IEC IN ESTABLISHING AN INTESTINAL BARRIER AND ITS
IMPACT ON INTESTINAL HOMEOSTASIS
IECs significantly contribute to the establishment of a functional, tolerant
immunological barrier that protects against mucosal invaders without inflicting
pathological damage to the host. The first line of defense against inadvertent activation
of the lamina propria immune system consists of a specialized network of protein-based
connections that bind IECs together into a variably permeable barrier. These connections
consist of a large collection of proteins called claudins and occludins arranged on a
scaffold protein called zonulin (McCarthy, Skare et al. 1996). Exchanges to the claudin
and occludin components can be made rapidly by IECs in order to regulate
transmembrane molecular flow (Shen, Weber et al. 2011). Manipulation of the tight
junction (TJ) proteins can either open the spaces between IECs or more tightly constrict
them. In addition to TJ pore size, specific changes in the protein content preferentially
dictate the charge of the ions allowed to flow across the epithelial barrier. Aggressive
changes in ion flow across the barrier can actually induce a protective “flushing” effect in
response to certain infections (Schulzke, Ploeger et al. 2009). In concert with ion flow,
changes to TJ composition also influence permeability of the epithelial barrier
permeability to the transmucosal flux of bacterial products. In a process closely tied to
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IEC detection and identification of bacterial components, IECs continuously adjust the
permeability of the barrier function (hence, the term variably permeable membrane)
(Kirpich, Feng et al. 2012). Through the same mechanisms that microbial components
elicit an immune response in formal immune cells, these microbial antigens can also
induce IECs to secrete the same important effector cytokines, as well. IECs have been
found to secrete a wide variety of cytokines polarized to the Th1 type of immune
response (León, Sánchez et al. , Tiittanen, Keto et al. 2013), including IFN-γ, TNF-α, IL1β, IL-6, IL-17, IL-12/23, IL-22, and IL-33 in our hands. Although many of these
cytokines have demonstrated direct effects on barrier permeability, the first three (IFN-γ,
TNF-α, IL-1β) have garnered the most attention in regard to their role in barrier
dysfunction related to IBD. In the ultimate analysis, pro-inflammatory cytokine secretion
serves as a tool for local communication between IECs. The signal sent out depends on
the input detected through the interaction of bacterial products with the sensory
machinery contained within IECs. In individuals susceptible to IBD, ineffectual signal
detection or defective signal transduction leads to inappropriate secretion of
inflammatory cytokines (Su, Shen et al. 2009, Ulluwishewa, Anderson et al. 2011). This
unintended activation of a tightly controlled feedback loop, in turn, further degrades
epithelial barrier integrity and sensitizes lamina propria immune components to bacterial
antigens, ultimately resulting in an expansion of the local immune system activities.

1.1.5 HOW IECS MAINTAIN HOMEOSTASIS
Although IECs establish a robust barrier function, the intestinal epithelium is not
invulnerable to bacterial invasion by bacterial pathogens.
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In order to facilitate

monitoring for the presence of pathogens, the immune system has developed a
mechanism to survey the microbiome (Didierlaurent, Sirard Jc Fau - Kraehenbuhl et al.
2002). This is accomplished, in part, by non-specific mechanisms, such as epithelial
transcytosis of bacteria and their antigens by standard IECs, as well as, uptake by
specialized enterocytes called M-cells (figure 2). M-cells may also be able to selectively
concentrate their uptake of pathogenic organisms through receptor-mediated transcellular
transport mechanism, such as the glycoprotein GP2-FimH interaction (Ohno and Hase).
Goblet cells have also been shown to transport soluble bacterial proteins to sub-epithelial
dendritic cells (Peterson and Artis 2014). Finally, sub-epithelial dendritic cells extend
dendrites across the epithelial barrier into the lumen to directly sample luminal contents,
and then transport both viable bacteria and soluble antigens to mesenteric lymph nodes
during their migration to the draining lymph nodes (Rescigno, Urbano et al. 2001).
Dendritic cells generally acquire a tolerogenic tone as they mature during their transit to
their eventual destination in the mesenteric lymph node in patients without IBD
(Rescigno 2014).
sum

total

sampling

of

The
these

techniques

typically form the basis
for setting the state of
immune tolerance.

Figure 2. Contribution of IECs to homeostasis.
IECs form a physical and immunological barrier against
luminal bacteria. (From: Peterson and Artis 2014)
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While

these

same events occur in

IBD patients, the perturbations within the maturation process that diminish mucosal
tolerance in IBD patients still evade complete understanding.

One final contributor to the lamina propria immune compartment’s state of
tolerance and overall intestinal homeostasis comes from the IECs themselves. IECs act
as frontline receptors for microbial organisms.

They express a variety of pattern

recognition receptors, including Toll-like receptors (TLR), NOD-like receptors (NLR),
and RIG-I-like receptors (RLR) (Gallo and Hooper 2012). These receptors assist in
maintaining tissue homeostasis.

The initial indication that IECs contributed to the

induction of tolerance came from studies of TLR deficient mice. TLR stimulation by
bacterial ligands was required to maintain epithelial homeostasis and to repair injured
epithelial barriers (Ostaff, Stange et al. 2013). From that work emerged the fact that
several compensatory reactions emerge after TLR stimulation, including the upregulation
of epidermal growth factors, intestinal trefoil factor 3, heat-shock proteins, and tight
junction proteins responsible for enhancing epithelial barrier resistance to paracellular
antigen flux (Putsep 2000). In concert with TLRs, additional receptor classes such as the
Nod-like receptors and other inflammasome components have been found to be important
contributors to the IEC regulation of GI homeostasis. NLRs and inflammasomes play a
vital role in epithelial restitution in the aftermath of bacterial invasion.

Given the extensive array of bacterial sensors present on IECs, the propensity to
secrete inflammatory cytokines, and the close proximity to trillions of bacteria, the
interpretation of how homeostasis and immune tolerance can be maintained in this setting
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is a complicated formula. When this fine balance is disrupted, inflammatory bowel
disease ensues. IECs express specific negative regulators of pattern recognition receptor
(PRR)-dependent pro-inflammatory responses to commensals (Didierlaurent, Sirard Jc
Fau - Kraehenbuhl et al. 2002). Another mechanism for differentiating commensal
organisms from pathogenic mechanisms has to do with the placement of the different
bacterial sensors. Due to the polarized anatomy of IECs from apical to basolateral, with
the tight junction complex providing a hard boundary between the two, differential
responses to microbial exposure can occur. Apical exposure of TLR-9 to appropriate
ligands results in a net inhibitory effect on IEC responsiveness due to stabilization of
IκB, while basolateral exposure leads to canonical activation and subsequent nuclear
translocation of NF-κB (de Kivit, van Hoffen et al. 2011). This provides a mechanism
for generating tolerance when bacteria are appropriately located, while permitting
activation of an immunological response in the setting of a mucosal breach.

The

intracellular sensor NOD2 provides an additional example of the importance of the site of
localization to the impact on immune response.

Upon stimulation with muramyl

dipeptide (MDP), the leucine-rich repeats of NOD2 associate with the basolateral
membrane based FERM and PDZ domain containing 2 (FRMPD2) scaffold protein,
leading to induction of an inflammatory response (Boyle, Parkhouse et al. 2014).
Location of pathogen associated molecular pattern (PAMP) stimulation may not be the
only mechanism by which IECs determine whether an inflammatory response is needed
or not. One additional mechanism may lie with the ability to recognize danger in relation
to microbial viability, based on recognition of bacterial products by viability-associated
PAMPs that can differentiate intact, alive microbes versus non-infectious debris
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(Mourao-Sa, Roy et al. 2013). This feat is accomplished by detecting virulence factors
present on viable organisms, such as bacterial secretion systems or intact toxins (Keestra
and Bäumler 2014). This level of differentiation provides another mechanism for IECs to
discern between the need to activate an immune response against a pathogen versus
maintaining tolerance to a commensal organism.

In their role as intestinal gatekeeper, IECs constituting the intestinal border selfregulate in response to bacterial signals.

As detailed previously, mucin layer

maintenance depends on the interaction of bacterial components with TLR sensors, antimicrobial peptide (AMP) production requires the presence of commensal organisms, and
polymeric immunoglobulin receptor (pIgR)-mediated transport of IgA across the
epithelial barrier is dependent upon the sensing of commensal bacteria by IECs.
Completing the lineup of barrier functions dictated by the sensing of bacterial
components, TJ protein redistribution by IECs to apical locations in the border structure
occurs in part due to the effects of bacterial-dependent TLR-2 triggering (Ulluwishewa,
Anderson et al. 2011).

1.1.6 IECs CONTRIBUTE TO IMMUNE REGULATION
IECs actively participate in the regulation of immune cells inhabiting the lamina
propria located just beneath the epithelium through the use of immunoregulatory signals.
Both the innate and adaptive immune compartments receive IEC mediated instruction
through the production of cytokines such as thymic stromal lymphopoetin (TSLP),
transforming growth factor-β (TGFβ) and IL-25 (Peterson and Artis 2014). Additional

12

IEC signals deliver information to B-cells including TNFSF13 (APRIL) and TNFSF13b
(BAFF), which promote B-cell survival and plasma cell longevity.

Resident

mononuclear cells receive tolerogenic signals from IECs via production of TSLP, TGFβ
and retinoic acid. These factors depend on commensal bacteria for their regulation. Two
particular populations of mononuclear cells reside just below the epithelial layer: the preDC derived CD11c+CD103 dendritic cell (DC), and the monocyte derived
CD11clowF4/80CX3CR1hi resident macrophages (Rogler, Hausmann et al. 1998, Farache,
Koren et al. 2013). The intestinal epithelial dendritic cell performs a crucial step in
inducing adaptive T cell responses, and therefore plays a pivotal role in determining the
immune tone of the intestinal homing T cell population. Lamina propria (LP) residing
DCs collect both luminal, as well as, LP derived bacterial components (Martín-Fontecha,
Lanzavecchia et al. 2009). After activation, antigen-carrying DC migrate to regional
lymph nodes to educate naïve T cells (Rescigno 2014). Using retinoic acid as a cue, DCs
initiate antigen responsive naïve T cell imprinting to an intestinal phenotype by upregulating the specific integrin profile combining the α4 integrin with the β4 integrin
(Mora, Bono et al. 2003, Iwata, Hirakiyama et al. 2004, Johansson-Lindbom, Svensson et
al. 2005, Jaensson, Uronen-Hansson et al. 2008, Mora and Von Andrian 2008). This
particular combination interacts with MadCAM-1 to effect homing of activated T cells
back to the intestinal mucosa during periods of inflammation (Arihiro, Ohtani et al.
2002). The presentation of additional co-stimulatory signal during T cell activation allow
the migratory DC to condition the naïve T cell into an appropriate effector T cell,
effectively providing a mechanism for the DC to communicate the signals that it received
from the IECs prior to migration to the MNL (Reis e Sousa 2004). In contrast, non-
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migratory CX3CR1hi lamina propria-based macrophages, located in close proximity to
the IEC layer, have down-regulated CD14 and function primarily as phagocytes clearing
out cellular and microbial debris from pathogenic or commensal organisms that traverse
the epithelial barrier (Bain and Mowat 2014). In contrast to newly migrated monocytes
that actively participate in active inflammatory processes (Zigmond, Varol et al. 2012),
these resident macrophages mainly participate in the promotion of tolerance, by
promoting expansion of regulatory T cells (Hadis, Wahl et al. 2011) and actively
secreting IL-10, an anti-inflammatory cytokine that suppresses activated T cells. IECs
promote this behavior via secretion of TSLP, TGFβ, retinoic acid, and semaphorin 7A
signaling via αvβ1 integrin expressed on CX3CR1hi macrophages (Kang, Lee et al.
2007).

Another class of immune cells named innate lymphoid cells (ILCs) provide
another critical contribution to intestinal homeostasis (Sonnenberg and Artis 2015). This
class of cells lack adaptive effector cell properties, such as antigen specific receptors
found in B and T cells, and are generally found at barrier surfaces such as the lamina
propria of the intestine (Sonnenberg and Artis 2015). These cells function as regulators
of tissue homeostasis, inflammation and innate early response to infection and consist of
three subtypes (Artis and Spits 2015). Group 1 (ILC1s) includes classical natural killer
(NK) cells which are characterized by secretion of Th1 cytokines IFN-γ and TNF-α. NK
cells can kill target cells via cytotoxic activity, but other ILC1s can only secrete cytokines
(Artis and Spits 2015). Non-cytotoxic ILC1s may play a role in IBD (Bernink, Peters et
al. 2013, Fuchs, Vermi et al. 2013). Group 2 ILCs (ILC2s) secrete IL-5 and IL-13, the

14

Th2 type cytokines (Artis and Spits 2015). This class of ILCs may play a role in food
allergy or wound repair. Their proliferation and activation depend on IEC production of
IL-25, IL-33 and TSLP (Moro, Yamada et al. 2010, Neill, Wong et al. 2010, Price, Liang
et al. 2010, Mjösberg, Bernink et al. 2012). Group 3 ILCs perform dichotomous roles
depending on the environmental conditions communicated by IECs. They can secrete IL17 in response to IEC secretion of IL-23 or IL-22 in response to commensal induced IEC
secretion of IL-7 (Qiu, Guo et al.).

This differential signaling pattern provides a

mechanism for IEC to influence this lamina propria immune component to provide
appropriate response based on actual conditions encountered by the epithelium. Their
importance in human disease is not clear at this time.

However, IL-22 supports

containment of resident bacteria in gut-associated lymphoid tissue (Hanash, Dudakov et
al. 2012, Sonnenberg, Monticelli et al. 2012, Kirchberger, Royston et al. 2013), in
addition to directing γδ T cells in an immediate innate response to invading pathogens
(Edelblum, Singh et al.).

ILC3-derived IL-17A provides a predominantly pro-

inflammatory effect in the setting of human IBD (Buonocore, Ahern et al. 2010,
Geremia, Arancibia-Cárcamo et al. 2011, Coccia, Harrison et al. 2012). In addition, IECs
play a direct role in regulating IEC3s. Under the influence of commensals, IEC produce
IL-25, which suppresses IL-23 production by macrophages and decreases IL-22 secretion
by ILC3s (Sawa, Lochner et al. 2011). Commensals also direct IECs to produce IL-7,
which stabilizes the transcription factor retinoid-related orphan receptor γt (RORγt)
(Satoh-Takayama, Vosshenrich et al. 2008, Vonarbourg, Mortha et al. 2010) and
promotes ILC3 production of IL-22. Retinoic acid has also been shown to enhance IL-22
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production, which aids in the suppression of experimental murine colitis (Mielke, Jones
et al. 2013).

Other tissue resident T cells consist of specialized intraepithelial lymphocytes that
reside in close contact with IECs, consisting of both activated conventional T cells as
well as a smaller subset of T cells expressing a restricted repertoire of T cell receptors,
which includes both γδ and NK T cells (Cheroutre, Lambolez et al. 2011). These T cells
also receive bi-directional instructions from IECs to serve as an immediate mediator of
cytotoxic responses to infectious organisms. Conventional T cells residing in intestinal
tissue are primed to serve as rapid responders in the setting of active inflammation or
infection and also provide the memory effect needed to mount a response to recurrent
infections with a previously encountered infectious agent. CD8+ T-cells with an αβ T
cell receptor constitute a significant proportion of the IEL population in humans
(Gebhardt, Mueller et al. 2013). These tissue resident T cells interact with IECs via
CD103 (αEβ7), which binds to E-cadherin expressed by IECs (Schön, Arya et al. 1999,
Sathaliyawala, Kubota et al. 2013). In fact, this interaction with CD103 and E-cadherin
has been shown to be important in acute infection with mucosal pathogens such as S
typhimurium, as the CD103 directs γδ T cells into the lateral intercellular space between
IECs (Edelblum, Singh et al. , Cerutti 2008), through an unknown mechanism dependent
on the presence of IL-22. Finally, IECs appear to facilitate the positive selection and
expansion of high affinity TCR CD8+ TRMcells (resident memory) expressing CD8α (also
known as CD8αα+ IELs) (Farber, Yudanin et al. 2014).
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IgA secreting plasma cells play a significant role in maintaining defenses against
pathogens and perhaps even regulating commensals. Maturation of naïve B cells into
mature IgA-secreting plasma cells requires priming signals from mucosal DC plus live
bacteria (Macpherson and Uhr 2004, Cerutti 2008). These mucosal DCs have been
conditioned by IEC-derived signals to promote IgA class switching and a gut homing
phenotype, via the effects of nitric oxide, IL-10 and retinoic acid combined with TGFβ
signaling (Macpherson and Uhr 2004, Mora, Iwata et al. 2006, Mora and Von Andrian
2008). In the presence of a cognate CD4 T cell response, CD40L expression provides a
necessary signal to activate class-switch recombination (CSR) within the B cell. In the
absence of a cognate CD4 T cell response, CSR can occur under the influence of IEC
expression of APRIL and BAFF signaling through transmembrane activator and CAML
interactor (TACI) and BAFF receptor (Litinskiy, Nardelli et al. 2002, Salzer, Chapel et al.
2005, He, Xu et al. 2007, Xu, He et al. 2007). Commensals influence NF-κB activation
which enhances IEC expression of TSLP signaling. This, in turn, enhances mucosal DC
expression of APRIL and BAFF production and amplifies B cell stimulation.

Far from serving as just a mechanical barrier, the IECs of the intestinal mucosal
interface function as a sensory organ for evaluating the luminal microbial environment,
act as translators of the prevailing conditions to educate the underlying immune system,
and provide both stimulatory and regulatory signals to evoke a graded response to
invasive events when a counter response is necessary. Despite the central importance of
the intestinal epithelium in coordinating and effecting immune responses, its role in
inflammatory bowel disease has been relatively discounted, especially when considering

17

targets for IBD therapy. The majority of work performed to this date has targeted
primary and secondary immune cells. Failure to consider the mucosal barrier function
likely accounts, in part, for failures that have been seen with therapies directed at
classical immune cells.

1.1.7 IBD: NOT JUST A DISORDER OF THE IMMUNE SYSTEM
The fundamental basis of IBD remains a hotly debated topic, with most theories
taking the view that IBD results from a dysfunctional relationship between the microbiota
residing in the intestinal lumen and the immune system lining the other side of the
intestinal epithelial barrier.

Many lines of evidence from the basic sciences have

established the fact that IBD requires the presence of commensal organisms, but the idea
that a loss of tolerance to commensals leads to IBD became entrenched in the collective
thinking after Duchmann et al showed that immune cells isolated from the intestines of
IBD patients responded vigorously to sonicates of both autologous and heterologous
microflora, while immune cells from normal patients only responded to heterologous
microflora (Duchmann, Kaiser et al. 1995). The general mechanism explaining the
inappropriate activation assumes a loss of immune tolerance to the intestinal flora. One
explanation assumes that the microflora maintains its baseline characteristics in both
quantity and composition, while immune tolerance breaks down and a defective mucosal
effector T cell arises and overreacts to commensal organisms. Collateral damage to the
lining of the GI tract occurs as a consequence of the chronic inflammation. Another
competing hypothesis contends that the primary problem arises due a shift in the
composition of the intestinal microbiome, which initiates an immune response directed
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against the interlopers.

The ensuing inflammation results in chronic, unremitting

intestinal inflammation.

The role of bacteria in IBD pathogenesis has been well established. Host-microbe
interactions are required for the normal development of the host immune system and
effective responses to intestinal pathogens. The innate immune system stands up as the
first responder in response to pathogen invasion. The innate immune system is also
necessary and sufficient for the initiation of IBD, while the adaptive immune system is
not.

Animals without an adaptive immune system, such as the Rag-/- and severe

combined immunodeficient (SCID) mice, do not spontaneously develop colitis, unless
they are exposed to a trigger of innate immunity, such as the administration of dextran
sodium sulphate (DSS), anti-CD40 antibody, or Helicobacter hepaticus (Dieleman,
Ridwan et al. 1994, Buonocore, Ahern et al. 2010, Maloy and Powrie 2011). However,
the absence of an adaptive immune system can protect against the development of colitis
in certain genetically susceptible animal models. These data suggest that the control or
prevention of an innate immune response could protect against the initiation of an IBD
event. In chronic IBD, the role of the adaptive immune system takes over, as evidenced
by the large numbers of activated T cells. The factors responsible for the induction of a
pathologic adaptive T cell immunity against commensal organism have not been fully
elucidated, but many clues point to dysfunction of the IECs as a significant contributor to
the maladaptive response.
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The main factors that appear to contribute to the breakdown in functional
tolerance found in IBD include changes in the microbiome, defects in normal barrier
function, dysfunction in the autophagy pathway, and abnormal responses to stress in the
form of unfolded proteins. Normal compensatory regulatory functions responsible for
reining in the active immune response fail to take hold, and the initial immune response
gains steam and careens out of control.

1.1.8 CONTRIBUTION OF THE MICROBIOME TO IBD
Our understanding of the complexity of the intestinal microbiome continues to
evolve. In fact, you just have to wait until your next meal for the composition of your
microbiome to change (David, Maurice et al. 2014). Although IECs do not appear to
directly impact the microbiome, dietary habits and other environmental factors implicated
in the development of IBD have been shown to influence the relative composition of
bacteria (Hansen, Gulati et al. 2010). Recent evidence suggests that some species play a
larger role in promoting inflammation than others. Table 1 summarizes some of the
classes felt to be important to the pathogenesis of IBD:
Table 1. Microbiota changes important to IBD susceptibility
Decreased

Increased___________________

Bacteroides (SCFA)

Actinobacteria

Clostridium IXa and IV groups (SCFA)

Proteobacteria

Bifidobacterium populations

Bacteriodetes

Faecalbacterium prausnitzi (SCFA)

B. fragilis

Firmicutes

Mucosal adherent bacteria (AIEC)

Adapted from Frank et al. (Frank, Amand et al. 2007).
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Many of the bacteria seen as protective against IBD produce short chain fatty
acids (SCFA). Clostridium and Bacteroides species are the main producers of SCFAs in
the human colon (Wong, de Souza R Fau - Kendall et al.). One particularly robust
producer of SCFA, F. prausnitzi, has been shown to provide a strong anti-inflammatory
effect in immune cells (Sokol, Pigneur et al. 2008) and to be deficient in patients with
IBD (Sokol, Seksik et al. 2009). The sensing of other luminal inhabitants, such as fungal
organisms may also play a role in immune tolerance. This has been demonstrated by the
fact that dectin-1 knock out (KO) animals are more susceptible to induced colitis (Frank,
Amand et al. 2007).

1.1.9

BARRIER

FUNCTION

DISTURBANCES

AUGMENT

MICROBIAL

STIMULATION OF MUCOSAL IMMUNITY
Patients with both active and quiescent IBD have a reduced number of goblet
cells within the intestinal mucosa (Xavier and Podolsky 2007). Genes encoding mucins
are generally underexpressed, resulting in the presence of thin, ineffective mucin layers.
Animal models with defects in mucin genes are highly susceptible to IBD.

Intestinal epithelial barrier permeability impacts many human disease states,
especially IBD (McGuckin, Eri et al. 2009).

Cytoplasmic-based proteins (zonnula

occludens) and integral membrane-based proteins (claudins and occludins) knit the
enterocytes forming the intestinal epithelial layer together in a manner that isolates the
space below (lamina propria) from the microbial antigens present in the lumen of the
intestines (Ivanov 2012). Defects of apical junctional complexes lead to permeable
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epithelial barrier as evidenced by decreased epithelial electrical resistance and increased
markers of flux such as fluorescein isothiocyanate (FITC) (Peterson, Costantini et al.
2010). These findings likely arise from alterations in the composition of tight junction
proteins that precede any manifestation of disease. Changes in the ratio of pore forming
claudins, such as claudin 2, claudin 4, and claudin 8 to pore tightening claudins, such as
claudin 1, allow for increased ion flux across the epithelial border, resulting in osmotic
diarrhea (Zeissig, Bürgel et al. 2007, Förster 2008). All components of the integral
membrane-based TJ proteins, including occludin, cadherins, as well as, catenins have
been found to be underexpressed in IBD patients (Weber and Turner 2007, Reuter and
Pizarro 2009). Tight junction protein expression appears to be regulated through a
variety of mechansims, including certain cytokines expressed by IECs and immune cells
of the lamina propria (Nusrat, Turner et al. 2000, Weber and Turner 2007, Zeissig,
Bürgel et al. 2007, Benjamin, Makharia et al. 2008)

1.1.10 IMPACT OF DEFECTS IN AUTOPAGHY ON HOMEOSTASIS
Defects in autophagy play a role in the pathogenesis of IBD (Tian, Kabi et al.
2001). Genome-wide association searches (GWAS) identified ATG16L1 as an important
mutation in IBD patients (Fowler, Doecke et al. 2008).

Animals transfected with

defective ATG16L1 become more susceptible to both the DSS model and an infectious
model of IBD involving Y. enterocolitica (Saitoh, Fujita et al. 2008, Murthy, Li et al.
2014). Paneth cells in terminal ileum of genetically altered animals resemble those seen
in human Crohn’s disease terminal ileum (Cadwell, Patel et al. 2010). While autophagy
plays an important role in maintaining cellular energy stores during periods of stress or
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starvation, it is also an integral process in handling bacterial products (Scharl and Rogler
2012).

Defects in the proteins associated with autophagy can lead to ineffective

degradation of phagocytosed bacteria and dysfunctional organelles. Disruption of the
normal autophagy pathway leads to intracellular accumulation of secretory granules and
subsequent decrease in antimicrobial peptide secretion (Kaser and Blumberg 2011). In
fact, infection with norovirus in humans drives a pro-inflammatory phenotype similar to
that seen in IBD (Kaser, Lee et al. 2008). Accumulation of antimicrobial peptides within
the IECs leads to increased microbial contact with the epithelial barrier, activation of
inflammation, and increased susceptibility to colitis.

1.1.11 STRESS RESPONSE ALTERED IN IBD PATIENTS
Circumstances that lead to accumulation of misfolded proteins in the endoplasmic
reticulum (ER), such as shock, heat stress, metabolic stress, or bacterial infection
typically induce a corrective cellular response called the misfolded protein response
(Celli and Tsolis 2015). Misfolded proteins may occur in the setting of genetic mutations
or environmental stimuli that are not conducive to normal protein, such as starvation
(glucose/protein), hypoxia, or heat shock (Kaser and Blumberg 2010). Infection or
inflammation also leads to stress within the endoplasmic reticulum, particularly in cells
with a robust secretory function. The accumulation of misfolded proteins within the ER
can result in disruption of normal cellular function. Affected cells can attempt to rescue
themselves from death by activating the unfolded protein response (UPR) (Kaser and
Blumberg 2009). Highly active secretory cells, such as Paneth cells located at the base of
intestinal epithelial crypts, are highly sensitive to ER stress and require a robust UPR to
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maintain homeostasis and normal function (Kaser and Blumberg 2009). A normal UPR
to ER stress consists of upregulated synthesis of particular chaperone proteins and
induction of autophagy to enhance breakdown of misfolded proteins (Kaser and
Blumberg 2009). An irreversible accumulation of misfolded proteins initiates apoptosis
of stressed cells.

One method of recognizing misfolded proteins utilizes inositol

requiring enzyme 1 (IRE1). Upon the recognition of misfolded proteins, IRE1 splices the
mRNA of X box binding protein 1 (XBP1) into a transcriptionally active form that
subsequently induces translation of a family of proteins responsible for managing the
UPR (Kaser and Blumberg 2011). XBP1 has been identified as a risk factor for both UC
and CD (McGovern, Gardet et al. 2010, Kaser and Blumberg 2011), and Paneth cells in
the epithelium of XBP1 deficient animals die by apoptosis, leading to spontaneous colitis
and enhanced susceptibility to enteric infections. Paneth cell loss leads to enhanced
barrier permeability and inflammatory tone (Mumphrey, Changotra et al. 2007). Other
mutations in UPR have been associated with IBD in GWAS searches, such as
orsomucoid like gene 3 (ORMDL3) and anterior gradient 2 (AGR2) (Zheng, Rosenstiel
et al. 2006, Kaser, Lee et al. 2008, Kaser, Flak et al. 2011). The intersection of defects in
the inter- and intracellular bacterial sensing mechanisms in conjunction with the
apparatus responsible for regulating apoptosis in the setting of overwhelming stress
response or defective unfolded protein response provides a fascinating insight into how
epithelial handling of bacterial products from commensal organisms could be involved
with the incitement of the heightened state of inflammation found in IBD, without an
overt infectious trigger accounting for the disease state.
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1.1.12 LINKING ABNORMAL IEC FUNCTION TO DYSFUNCTION OF INNATE
IMMUNE RESPONSE
Extra- and intracellular receptors help the intestinal epithelial cells and immune
cells discern between friend or foe by discriminating between different bacterial
components. As just discussed, intracytoplasmic bacterial sensors have been linked to
the indirect development of inflammation and altered immune responses to commensal
organisms through defects in intracellular sensors tied to inadequate autophagic
responses.

However, this process can be directly linked to the initiation of an
inflammatory response, as well, through shared signaling
components. Bacterial components can result in direct triggering
of a parallel immune response via inflammasome activation
(Hsu, Ali et al. 2008).

The inflammasome represents a

confluence of three individual components, including a NODlike (NRL) receptor, an adapter protein called ASC, and caspaseFigure 3. Caspase-1
activation pathway.
(From: Newton, 2012)

1.

Oligomerization of these three components into a single

structure result in the formation of an inflammasome,

responsible for cleaving certain immature cytokines (Dinarello 2002). Inflammasome
activation by bacterial or viral components is required to initiate the cleavage of
intracellular pro-cytokines (pro-IL-1β, pro-IL-18, and pro-IL-33), ultimately leading to
the secretion of active cytokines and the subsequent induction of an immune response
(Dinarello 2002, Martinon and Tschopp 2007).

Inflammasome activation by

PAMP/DAMP sensing also provides a basis for linking the mutated variants of NOD2
(Newton 2012), a genetic susceptibility factor found in some Crohn’s disease patients,
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and the clinical manifestations of IBD (Cho 2001). After binding with MDP, activated
NOD2 binds directly to caspase-1 via its N-terminal CARD domain and activates
caspase-1 (figure 3), which subsequently cleaves immature, pro-cytokines such as IL-1β
and IL-18 into their active forms, leading to the initiation of a robust innate immune
response to bacterial penetration (Hsu, Ali et al. 2008). Deficiencies in this system lead
to inadequate host immune responses in the Crohn’s disease patient and the potential for
overaggressive adaptive responses to uncontrolled bacterial contact with the intestinal
epithelium. Further supporting this concept, multiple lines of evidence identify that
inflammasome activation acts as a pivotal regulator of intestinal homeostasis, by coupling
its ability to detect the presence of intracellular bacterial components to pathways for
augmenting protective measures such as protective mucin and antimicrobial peptide
(AMP) synthesis (Kaser and Blumberg 2011, Peterson and Artis 2014, Wlodarska, Thaiss
et al. 2014). Therefore, the same germline mutations that are implicated in inappropriate
immune responses to commensal organisms likely further compound the underlying
inflammation of IBD by impairing the homeostatic processes that protect against
inadvertent immune activation. Since innate lymphocyte recruitment and antimicrobial
peptide secretion is frequently stimulated by the high levels of IL-1β and IL-18 secreted
by IECs (Hornef and Fulde 2014, Bedi, McNair et al. 2015), intracellular processing of
these pro-cytokines serve as yet another link between the microbial sensing function of
NODs and NLRPs by IECs to activation of innate immune system responses. It appears
that inappropriate sensing by defective intracellular sensors in some forms of IBD
provides a perfect storm leading to enhanced bacterial proliferation and subsequent, over
aggressive immune responses.
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1.1.13 ROLE OF IECs IN MUCOSAL INFLAMMATION
Since the initial reports that IECs secrete various cytokines (Stadnyk 1994),
evidence supporting the IEC as a source of a staggering number of immune mediating
proteins has been steadily accumulated (Peterson and Artis 2014). The type of bacteria
or immune cells interacting with IECs influence the type of cytokines and chemotactic
factors secreted (Reinecker and Podolsky 1995, Haller, Bode et al. 2000, Borruel,
Casellas et al. 2003, Watson and Galán 2005, Tiittanen, Keto et al. 2013).

The

complexity of cytokines known to be affiliated with the two most common forms of IBD
has steadily grown, as has the catalog of cytokines identified from animal models and cell
lines (Mitsuyama, Sata et al. , Sher, D'Angelo et al. 1995, Ruffolo, Scarpa et al. 2007,
Seidelin, Bjerrum et al. 2010). However, several difficulties exist when correlating
animal model cytokine production with human disease states. First, measuring systemic
levels of cytokines may miss localized paracrine effects from low level IEC secretion.
Second, cytokine profiles may vary greatly between diseased mucosa and adjacent
normal tissue.

This heterogeneity relates, in part, to the complex composition

characterizing cells of the intestinal epithelium. Functional specialization of certain
mucosal components, such as those associated with microfold (M) cells (specialized
epithelial cells covering the follicle-associated epithelium responsible for augmenting
antigen transcytosis) may enhance susceptibility to inflammation due to their close
proximity to mucosal immune cells (Kucharzik, Lügering et al. 2000, Gullberg and
SÖDerholm 2006).

Lastly, established inflammation generates clinically apparent

symptoms prompting endoscopic evaluation. Therefore, most biopsy specimens come
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from chronically diseased patients. A true time course experiment, easily done with cell
lines or cells from peripheral blood, becomes exceedingly difficult in humans, when the
inconvenience or safety ramifications of serial colonoscopies at a close enough interval to
make meaningful observations is considered. Therefore, most descriptions of clinical
IBD represent a “snap shot”, or moment in time. Accurate information distinguishing
precursor environment from conditions during clinically apparent inflammation or even
during the resolution phase are non-existent. These limitations have certainly impacted
clinical research in dramatic fashion.

1.2 IMPACT OF DIETARY COMPONENTS ON INFLAMMATION
Diet plays a significant role in health and disease. The benefits of whole grains
have been recognized since the time of Hippocrates (Slavin and Lloyd 2012), and fresh
fruits and vegetables have been shown to protect against a number of metabolic diseases
such as diabetes (Mursu, Virtanen et al. 2014), stroke and heart attack (He, Nowson et al.
2007), and even cancer (Mursu, Nurmi et al. 2008). Many of the benefits of a diet high in
plant-based food items may have to do with the increased dietary fiber accompanying
such diets. Dietary fiber serves as a metabolic substrate for certain bacteria and can
preferentially shape a microbiome (Wu, Chen et al. 2011). This observation supports
results seen in a study that analyzed the fecal microbiomes from 3rd world children
growing up a rural African village compared to children from the 1st world city of
Florence, Italy, that identified significant differences in fecal microbiota based on dietary
intake (De Filippo, Cavalieri et al. 2010). In particular, children from Florence harbored
high levels of bacteria from the phylum Firmicutes, while the stool from children from
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Burkina Faso contained high levels of Bacteriodetes and low levels of Firmicutes (De
Filippo, Cavalieri et al. 2010). The high levels of dietary fiber intake from the African
traditional diet was considered to be a contributing factor to the population diversities
seen based on location. Because of the close proximity of the nutrient containing lumen
of the digestive tract to the intestinal epithelium, the effect of dietary components may be
most strongly manifested at the mucosal interface. These data also support a connection
between dietary intake, shifts in the microbiome, and increased potential for IBD.

1.2.1 ANTI-INFLAMMATORY COMPOUNDS FROM DIETARY SOURCES
A diet high in fruits and vegetables has aso been associated with protection
against inflammation (Watzl 2008). Many of the beneficial effects have been attributed
to the anti-inflammatory effects of phytochemicals. In fact, it has been estimated that a
diet rich in plant food supplies over 25,000 phytochemicals that are missing from the
highly refined diets typical of the Western diet (Rao 2003). Ingestion of tea has been
associated with health for decades, including protection from chronic inflammatory
disorders, diabetes, cardiovascular disease and even cancer (Higdon and Frei 2003,
Lambert, Hong et al. 2005, Yang, Lambert et al. 2006). Green tea has especially been
associated with benefits to health, likely due to the abundant polyphenols contained
within the unfermented tea leaves. Massive amounts of tea are ingested throughout the
world, second only to water in worldwide consumption (Costa, Gouveia et al. 2002,
Rietveld and Wiseman 2003).

Although total tea consumption exceeds 3 billion

kilograms worldwide, the type of tea varies dramatically by region.
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1.2.2 PROCESSING OF TEA FOR INGESTION
All tea begins as leaves collected from the tea bush, Camellia sinensis. The
simplest preparations of tea, white and green teas, start with the steaming of freshly
picked tea leaves (figure 4). Steaming stops polyphenol oxidation by phenol oxidase that
activates spontaneously after picking (Cabrera, Artacho et al. 2006).

After steam

fixation, tea leaves are sun dried and processed for consumption. White tea is made with
the youngest tea leaves, sometimes protected from light to limit the development of
chlorophyll, and contains the highest polyphenol concentration by weight. Green tea is
made from mature tea leaves, and incurs less manipulation during processing than black
or oolong teas, leading to the highest retention of original polyphenol content (Graham
1992). Oolong and black teas alternate methods of preparation to induce different taste
and appearance properties. Tea leaves bound for black and Oolong teas are crushed to
activate polyphenol oxidase and expose internal contents to oxygen. The oxidation
process is halted early for Oolong teas, but is allowed to continue until complete
oxidation of the polyphenol content to theaflavins and thearugibins has occurred in the
production of black teas (Roberts 1958). The oxidation process turns the tea leaves
black. Black teas are naturally oxidized and occasionally bacterially fermented, while
Oolong teas are always semi-fermented. Bacterial enzymatic digestion further alters the
catechin profile even more dramatically. Health benefits appear to track with the type of
tea consumed. Black tea consumption by Western countries and India accounts for 78%
of worldwide consumption, while 20% is consumed as green tea in Asian countries and
2% is imbibed as Oolong tea, mainly in Southern China (Balentine, Wiseman et al.
1997).
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While the benefits of tea ingestion seen in epidemiologic studies are intriguing,
the actual amount of tea required to receive a physiologically meaningful dose of EGCG
would equal approximately 32 cups of green tea. Therefore, the work laid out in this
dissertation is based on the concept of providing a concentrated dose of EGCG in a
pharmacologically relevant oral dose of polyphenols extracted from green tea leaves.

Figure 4. Stepwise process for creating different forms of tea from freshly harvested
tea leaves. The crucial step in maintaining a high polyphenol level in green tea has to
do with the panfrying/steaming/firing step, as this heat inactivates the enzymes
responsible for oxidizing polyphenolic compounds into theaflavins and thearugubins
characteristic of black teas. (Source: Wikimedia Commons).
1.2.3 CHEMICAL COMPOSITION OF TEA LEAVES
Tea leaves contain a complex mixture of chemicals, including the
methylxanthines (theobromine and theophylline) plus polyphenols (including the
flavonols kaempferol, myricetin, and quercetin along with the flavanol catechins and
flavanol gallocatechins) (Manach, Scalbert et al. 2004). Up to 30% of the dry weight is
made up of flavanols plus flavonols (Balentine, Wiseman et al. 1997). Green tea contains
the highest level of flavanols of any food source (Manach, Scalbert et al. 2004). Of the
biologically active compounds contained in green tea, the most potent impact on

31

inflammatory pathways has been ascribed to the polyphenol content (Crouvezier, Powell
et al. 2001). The main polyphenols found in green tea consist of a class of flavonoids
called green tea catechins (Sano, Tabata et al. 2001). Four main catechins make up the
bulk of all catechins (figure 5), including (-)-epigallocatechin gallate (EGCG-60%), (-)epigallocatechin (EGC-19%), (-)-epicatechin-3-gallate (ECG- 13%) and (-)-epicatechin
(EC-6%) (McKay and Blumberg 2002).

Figure 5. Structures of the predominant polyphenols found in green
tea. (Kim, Tan et al. 2013).
1.2.4 ATTRIBUTES OF GREEN TEA POLYPHENOLS THAT COULD BENEFIT IBD
Green tea polyphenols (GrTP) are potent anti-oxidants. The anti-oxidant
properties of the GrTP EGCG are approximately 25-100 times more powerful than those
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of vitamin C (Rice-Evans, Miller et al. 1996). The anti-oxidant properties of green tea
polyphenols can be attributed to their donation of hydrogen radicals to alkoxyl (RO•) or
peroxyl (ROO•) free radicals, converting them to more stable products (Wang, Kim et al.
2000). Many of the putative health benefits of tea are presumed due to the anti-oxidant
effects of the polyphenols (Salah, Miller et al. 1995).

One benefit may be cancer

prevention, as epidemiological studies suggest that regular consumption of tea reduces
the risk of cancer (Katiyar and Mukhtar 1996).

In support of this, tea, or more

specifically the polyphenol fraction, decreases the incidence of carcinogen-induced
malignancies in animal models (Stoner and Mukhtar 1995). One proposed mechanism of
action suggests that polyphenols induce apoptosis more readily in cancer cells than in
their natural counterparts (Chen, Schell et al. 1998, Yang, Liao et al. 1998, Suganuma,
Okabe et al. 1999, Ahmad, Gupta et al. 2000). Although epidemiological studies have
evaluated the beneficial effects of green tea based on ingestion of cups of brewed tea,
difficulty in changing dietary habits and in ensuring uniform concentrations of
polyphenol intake have led most investigators to resort to the use of a standardized form
of encapsulated polyphenol extract for clinical trials. Also, the amount of tea that would
need to be consumed to obtain an adequate dose of polyphenols would exceed the
threshold of tolerability for most people.

1.2.5 ANTI-INFLAMMATORY PROPERTIES OF GrTP
Another potential benefit of green tea polyphenols stems from their antiinflammatory properties.

Studies in animal models show that GrTP decrease

inflammation (Yang, de Villiers et al. 1998). Mice fed an extract of GrTP had decreased
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tumor necrosis factor-alpha (TNF-α) production in response to an injection of
lipopolysaccharide (LPS), and that ingestion of GrTP also prevented death following
administration of a normally fatal dose of LPS (Yang, de Villiers et al. 1998). Haqqi et al
(Haqqi, Anthony et al. 1999) reported that the ingestion of a green tea polyphenol extract
reduced joint disease in mice with adjuvant-induced arthritis, which suggests that green
tea may have a benefit in treating arthritic conditions, such as rheumatoid arthritis.
Varilek reported that GrTP reduced disease activity in the autoimmune disease model of
interleukin-2 deficient (IL-2-/-) mice (Varilek, Yang et al. 1999). These studies suggest
that green tea polyphenols may be beneficial in treating chronic inflammatory diseases.

Many potential mechanisms responsible for the observed anti-inflammatory and
anti-cancer properties of GrTP have been reported. One potential mechanism of action is
the inhibition of NF-κB activation, an oxidative-stress sensitive transcription factor that
regulates the expression of a wide variety of genes important in many cellular responses,
including inflammation, innate immunity, apoptosis and growth. EGCG has been shown
to decrease LPS-induced TNF-α production in the macrophage cell line RAW264.7 and
in peritoneal macrophages by blocking the activation of NF-κB (Yang, de Villiers et al.
1998). Lin and Lin similarly reported that EGCG inhibited LPS-induced inducible nitric
oxide synthase gene expression in mouse peritoneal macrophages by decreasing NF-κB
activation (Lin and Lin 1997). Ahmad et al showed that GrTP modulate NF-κB in
several cancer cell lines, rendering them susceptible to apoptosis (Ahmad, Gupta et al.
2000). These studies suggest that green tea modulates the activation of an important
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transcription factor that is responsible for activating many cellular functions, including
inflammation, immunity and programmed cell death.

1.2.6 PHARMACOKINETICS OF GrTP
The bioavailability of polyphenols from orally consumed tea has been difficult to
determine from epidemiological studies, due to variations in types of tea consumed,
differences in preparation methods, standardization of dosing based on cup size, etc.
Suganuma and co-workers found that EGCG was widely distributed throughout the body
of a mouse, with significantly elevated levels in the digestive tract, liver, lung, pancreas and
skin (concentrations in the colon were 5x higher than the serum) (Suganuma, Okabe et al.
1998).

Repeated dosing 6 hours later enhanced tissue levels in blood, brain, liver,

pancreas, bladder, and bone. These levels were 4-6 fold greater than those found following
the initial dose. These results suggest that frequent consumption of green tea enables the
body to maintain higher tissue concentrations of polyphenols.

Initial human studies

returned highly variable absorption rates, ranging from 0.2-2.0% of ingested polyphenols
(Unno, Kondo et al. 1996, Nakagawa, Okuda et al. 1997, Yang, Chen et al. 1998). The
variation was likely due to non-standardized forms of tea ingested. Circulating EGCG
existed mainly in the free form (>92%), while EGC and EC exist mainly in the conjugated
form (Lee, Maliakal et al. 2002). More recent studies by Chow et al. evaluated the human
pharmacokinetic parameters from consumption of a daily dose of a caffeine-free, well
standardized, EGCG enriched capsule of green tea extracts (Chow, Cai et al. 2001, Chow,
Cai et al. 2003, Chow, Hakim et al. 2005). However, the chronic consumption of 800mg
EGCG as Polyphenon E over 4 weeks led to > 60% increase in the area under the curve
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(AUC), when following a dosing schedule of 800mg of total EGCG once daily. Since the
accumulation ratio was calculated at <1.05, the authors postulated that the observed
increase of free EGCG was not related to drug accumulation after repeated dosing. Rather,
they felt that the 800mg dose of EGCG/Polyphenon E resulted in significantly elevated
EGCG levels in the gastrointestinal tract, subsequently inhibiting the pre-systemic
elimination of EGCG (Chow, Cai et al. 2003). This is an important consideration, as it
points to the fact that ample active constituent to induce the beneficial effects of EGCG on
NF-κB inhibition and immune regulation will be available at the important interface
between the microbiome and the epithelial cells lining the intestinal and colonic lumen.
One would expect, based on the pharmacokinetic data from Chow and Suganuma, that the
intestinal mucosal concentration of EGCG exceeds that of the serum.

1.2.7 SAFETY PROFILE OF GrTP
In human studies, single doses of up to 4.5 grams of green tea extract have been
given without adverse reactions (Yang, Chen et al. 1998). In extended dosing studies,
doses up to 1 g/m2 of green tea polyphenols three times daily (equivalent to 21-24 cups of
green tea/day) have been given for up to 6 months without evidence of toxicity (Pisters,
Newman et al. 2001). Several animal studies have been performed using GrTP. Three
grams/Kg in a single dose has been shown to be lethal for mice, while 500 mg/kg in a
single dose was not toxic to mice or rats. In mice, 100 mg/Kg daily for 6 weeks was not
associated with any evidence of toxicity. However, rats fed 500 mg/Kg daily for 3 weeks
developed steatohepatitis with moderately elevated ALT levels. In a recent phase II study
evaluating the safety and efficacy of green tea in cancer patients (given as an actual tea),
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69% of subjects experienced mild (grade 1 or 2) toxicity, mainly consisting of nausea,
insomnia, abdominal pain and diarrhea (Jatoi, Ellison et al. 2003). Most of these symptoms
were attributed to the caffeine content of natural green tea. In a recent phase I study
evaluating the caffeine free form of green tea extract known as polyphenon E, subjects
experienced only mild side effects, such as excess gas, upset stomach, nausea, and diarrhea,
at rates similar to those receiving placebo.

In patients receiving active therapy, the

symptom of nausea alone exceeded the placebo adverse event rate (Chow, Cai et al. 2003).

1.3 SUMMARY OF BENEFITS OF GrTP AND ROLE IN IBD
As detailed above, epidemiologic data suggests that the intake of bioactive
compounds from fruits and vegetables positively impacts health and homeostasis, and in
the case of green tea, its intake may protect against cancers and inflammatory disorders.
In fact, one of the most important tea derivatives, EGCG, has been shown to possess
many useful properties for treating inflammatory diseases. After putting this preliminary
data into context with the expanding knowledge behind the pathogenesis of IBD, the
potential impact from EGCG on IBD becomes increasingly apparent.

Based on

epidemiologic data described above, the most common focus of EGCG related research
has concentrated on preventing or treating various forms of cancer. EGCG has been
found to play a role in an expanding number of important processes related to cancer and
cell signaling. Unfortunately, the promising in vitro findings in cancer research have not
readily applied to in vivo evaluations of efficacy in human disease processes. While
others have narrowly focused on these issues and their role in cancer, we have attempted
to redirect these findings to the closely related discipline of IBD and translate key
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findings from non-IBD related research to support the use of EGCG in IBD. Given the
low systemic availability of EGCG but high exposure at the luminal interface of the
intestinal mucosa, we hypothesized that while this phenomenon caused EGCG to fail in
cancer research, we could harness all the beneficial properties in treating IBD.

We have taken a stepwise approach to evaluate the impact of EGCG on various
aspects of IBD pathophysiology. First, in chapter 3 we questioned whether EGCG could
be used as a preventative agent, as well as, a therapeutic agent in an animal model of DSS
induced colitis. We next conducted experiments testing the anti-inflammatory effects of
EGCG on activated immune cells taken from the systemic circulation, as well as,
stimulated epithelial cells as a surrogate for intestinal epithelial cells as detailed in
chapter 4.

However, data pointing to the fact that orally administered EGCG

concentrated at the epithelial barrier caused us to shift our focus in chapter 5 to
measuring the effects of EGCG and its influence of barrier permeability, as this has been
predicted to be an important front for controlling inflammation associated with IBD.
Finally, chapter 6 finishes off our exploration into the effects of EGCG on IBD with a
detailed report of our successful clinical trial using patients with active ulcerative colitis.
In summary, the data presented in this dissertation lays out a convincing argument for the
benefits of EGG in IBD and provides a springboard for exploring a whole new array of
IBD-related clinical applications.
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CHAPTER 2

MATERIALS AND EXPERIMENTAL METHODS

2.1 CELL CULTURE
Human cell lines were purchased from the American Type Culture Collection
(ATCC - Rockville, MD). Both Caco2 and HT-29 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 100 U/ml penicillin, 100 µg/ml
streptomycin, 0.1 mM nonessential amino acids, 10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), and 10% fetal bovine serum (FBS), at 37°C in a
5% CO2 environment. Culture medium was changed every 2-3 days. Caco2 cells (1x106
cells / well) were grown to 80% confluence prior to conducting experiments. Cells were
subcultured after partial digestion with 0.25% trypsin-EDTA, and passages 12-15 were
used. Caco2 and HT-29 cells grown on chamber slides (LabTek, Naperville, IL) were
used for determination of tight junction proteins, whereas Caco-2 cells grown on six-well
plates were used for immunoblotting analysis. For measurement of epithelial barrier
function, Caco2 cells were cultured on 24-well inserts (pore size 0.4 µm; BD
Biosciences, San Jose, CA). During co-culture experiments, EGCG was added to the
culture medium at noncytotoxic doses of 2.5, 5, 7.5, and 10 µg/ml.
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2.2 REAGENTS
The green tea catechin EGCG was purchased from Sigma Aldrich (St. Louis, MO) at
90% purity for administration to mice in drinking water, or at 99% purity for adding to
cell culture medium as above. The source of LPS was from Sigma Aldrich as well. The
LPS was derived from E. coli strain 0111:B4. Primary and secondary antibodies were all
obtained from Santa Cruz Biotechnology (Dallas, TX). DSD-PAGE gels in various
concentrations (6-12%) were obtained from Bio-Rad (Hercules, CA), as were blocking
buffers, lysis buffers, TWEEN, and trypsin. A Luminata Forte Western HRP substrate
chemilumiscent kit from Millipore (Billerica, MA) was used for imaging proteins by
Western blot. Elisa kits were obtained from R&D Systems and Antibodies-on-Line.com.
RNA isolation kits were obtained from Ambion (ThermoFischer – Grand Island, NY) and
MACS (Miltenyi – San Diego, CA). Primers for reverse transcriptase polymerase chain
reaction (RT-PCR) were obtained from Qiagen (Valencia, CA). Dextran sulfate sodium
(molecular weight 36-50,000) was obtained from MP Biomedicals (Santa Ana, CA). All
general lab chemicals were purchased from Sigma (St. Louis, MO).

2.3 CELL PROCESSING
Caco2 and HT-29 cells were used for cell culture studies due to the
reproducibility of growth rates, reliability of cultures, and known cytokine output based
on stimulation with LPS. A variety of analytical techniques were performed with the
cultured cells as described in subsequent sections.

2.3.1 PERIPHERAL BLOOD EX VIVO IMMUNE ASSAY
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Whole blood samples were collected in EDTA-containing vacuum tubes from
IBD patients and healthy controls. Samples were thoroughly mixed and centrifuged, then
divided and spiked with LPS (10 ng/ml) +/- EGCG. Samples were then incubated on a
gentle shaker plate overnight under standard cell culture conditions. After 24 hours,
plasma was collected by centrifugation and analyzed for cytokine levels.

2.3.2 CELL SEPARATION METHODS
Whole blood samples were collected in EDTA-containing vacuum tubes from
IBD patients and healthy controls. Samples were thoroughly mixed and centrifuged. The
isolated plasma was divided into separate culture tubes.

Non-control aliquots were

spiked with LPS (10 ng/ml) with or without EGCG. Samples were then incubated on a
gentle shaker plate overnight under standard cell culture conditions. After 24 hours, cells
were removed from the plasma by centrifugation and the supernatant was analyzed for
cytokine levels.

2.3.3 CELL ISOLATION TECHNIQUE
PBMCs were isolated from the buffy coat of IBD patients (n=25) and healthy
individuals (n=12) using Histopaque-1077 (Sigma Diagnostics, St. Louis, MO). The
PMBC concentration was brought to 1 x 106 cells/ml in culture medium.

The

subpopulations of CD14+ macrophages, CD4+CD45+RO+ (memory) T cells and
CD4+CD45+RA+ (naïve) T cells were isolated with microbead technology (Macs,
Invitrogen, Carlsbad CA) from the buffy coat aspirate.
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2.3.4 IMMUNE CELL STIMULATION
CD14+ macrophages were stimulated overnight (Sigma Aldrich, St. Louis, MO) at
a concentration of 10 ng/ml, while T cells subpopulations (CD4+CD45+RO and
CD4+CD45+RA) were stimulated by CD3/CD28 antibody coated plates. The stimulated
immune cells were incubated in culture medium alone or in combination with varying
concentrations of EGCG (2.5-10 µg/ml) at 37° C and 5% CO2 for an additional 24 hours.
All experiments were controlled with un-stimulated cells. At the end of the incubation
period, cells were extracted by centrifugation. Supernatants were collected by pipette to
measure pertinent secreted cytokine levels, while the pellets were used to isolate RNA for
measuring the expression of the targeted cytokine messages.

2.4

METHODS FOR DETERMINING EFFECT OF EGCG ON MODEL OF

INTESTINAL EPITHELIUM
Caco2 and HT-29 cells were grown to 80% confluence during experiments
designed to evaluate the effects of EGCG on cytokine expression and TJ proteins, as this
state of cell maturity most closely resembles intestinal epithelial cells during periods of
inflammation. During experiments measuring transepithelial electrical resistance (TER),
cells were allowed to grow to 100% confluence, which replicates epithelial cell behavior
during periods of homeostasis.

2.4.1 CACO2 MONOLAYER CELL CULTURE
Caco2 cells from the American Type Culture Collection (Rockville, MD) were
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 100 U/ml
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penicillin, 100 µg/ml streptomycin, 0.1 mM nonessential amino acids, 10 mM HEPES,
and 10% FBS, at 37°C in a 5% CO2 environment. Culture medium was changed every 23 days.

Caco2 cells (1x106 cells / well) were grown to 80% confluence prior to

conducting experiments. Caco2 cells were subcultured after partial digestion with 0.25%
trypsin-EDTA, and passages 12-15 were used. Caco2 cells grown on chamber slides
(LabTek, Naperville, IL) were used for determination of tight junction proteins, whereas
Caco-2 cells used for immunoblotting analysis were grown on six-well plates. For
measurement of epithelial barrier function, Caco2 cells were cultured on 24-well inserts
(pore size 0.4 µm; BD Biosciences, San Jose, CA). During co-culture experiments, LPS
with or without EGCG was added overnight to the culture medium at noncytotoxic doses
of 2.5, 5, 7.5, and 10 µg/ml.

2.4.2 IMMUNOBLOT ANALYSIS OF TIGHT JUNCTION PROTEINS
Protein was isolated by treating the monolayers with cell lysis buffer (20 mM
TrisHCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5
mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM sodium vanadate, 1
ug/ml leupeptin, 1 mM PMSF, and a protease cocktail set (100X Protease Inhibitor
Cocktail; Cell Signaling Technology, Danvers, MA) prior to mechanically separating the
cells with a cell scraper. Cell lysates were centrifuged and the clear supernatants were
removed. Protein measurements were determined using a BioRad Protein Assay kit
(BioRad, Hercules, CA). Aliquots containing 10 µg proteins were loaded on to 6 or 12%
SDS-polyacrylamide gel, depending on the protein being evaluated.

Proteins were

separated by electrophoresis at 120 V for 2 hours at room temperature. Proteins were
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transferred onto membranes (Trans-Blot Transfer Medium, Nitrocellulose Membrane;
Bio-Rad, Hercules, CA) for 1 hour at 120V at room temperature. The membranes were
incubated for 60 min in blocking solution (5% dry milk in PBS-Tween 20 buffer). The
membranes were incubated with primary Abs against claudins-1, -2, and -4, occludin, and
ZO-1 (Life Technologies, Grand Island, NY) in blocking solution at dilutions
recommended by the manufacturer for 16 hours at 4°C. The membrane was then washed
thoroughly and processed with horseradish peroxidase (HRP)-conjugated donkey antirabbit IgG (GE Healthcare, Piscataway, NJ) for each of the proteins of interest in
blocking solution at a 1:2000 ratio for 1 hour at room temperature and then developed
using Pierce ECL 2 Western Blotting Substrate (Thermo Scientific, Hudson, NH). The
membranes were exposed from 0.5 seconds to 20 seconds and the protein bands were
visualized by an enhanced chemiluminescence detection system (ChemiDoc MP Imaging
System, Bio-Rad, Hercules CA) and quantified by densitometry analysis (Image Lab 5.0
for MAC, Bio-Rad, Hercules CA).

2.4.3 MEASUREMENT OF CYTOKINE LEVELS BY ELISA
Cell culture supernatants were used to assay and quantitatively analyze several
IBD related cytokines (e.g., IL-1 β, INF-γ and TNF-α).

An enzyme-linked

immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN) was read by a
BioTek Plate Reader with Gen5 1.08 software (BioTek Instruments, Winooski, VT) at
540 nm to perform testing and analyze experimental results.
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2.4.4 ISOLATION OF RNA AND ESTIMATION OF CYTOKINE PRODUCTION BY
RT-PCR
Cell pellets were used to study the RNA expression of targeted cytokine messages
by real-time polymerase chain reaction (RT-PCR). The concentration and the quality of
isolated RNA were determined by measuring the 260/280 ratios. cDNA was prepared
using a Quantitect reverse transcription kit (Qiagen, Chatsworth, CA) after cleaning the
sample of any genomic DNA contamination. The cytokine expression was measured via
RT-PCR using TaqMan expression assays (Applied Biosystems, Branchburg, NJ) with βactin used as a control for RNA integrity and load equality. The 96-well RT-PCR
reaction plate was analyzed using a Step One plus RT-PCR system (Life Technologies,
Grand Island, NY).
Table 2. Primers used to perform RT-PCR.
Primer
Claudin 1
Claudin 4
Claudin 5
Claudin 8

Mucin 1
Mucin 2
MMP9
TNF-α

Human

Mouse

5’-GGCGACATTAGTGGCCACAGCATG-3’
5’-CGCGGATCCTTTCCGGGGACAGGAGCA-3’
5′-AGCCTTCCAGGTCCTCAACT-3′
5′-AGCAGCGAGTCGTACACCTT-3′
5′-GACTCGGTGCTGGCTCTGAG-3′
5′-CGTAGTTCTTCTTGTCGTAG-3′
5′-TCATCCCTGTGAGCTGGGTT-3′
5′-TGGAGTAGACGCTCGGTGAC-3′
5’-CCACCCATTTCACCAC-3’
5’-TACGCTGCTGGTCATAC-3’
5’-GCACTCACCATAGCACG-3’
5’-GGCCAGAGTCAATTGTAC-3’
5′-CGCAGACATCGTCATCCAGT-3′
5′-GGATTGGC CTTGGAAGATGA-3′
5′-CTCTTCTCCTTCCTGATCGTGGCA-3’
5′-GAAAGCATGATCCGGGACGTGGA-3’

5’-CGATGAGGTGCAGAAGATGA-3’
5’-CCAGTGAAGAGAGCCTGACC-3’
5’-GGCGTCTATGGGACTACAGG-3′
5′-GAGCGCACAACTCAGGATG-3’
5’-TGGAACGCTCAGATTTCATC-3’
5’-AGGAAGGCAACCCCTCTAAG-3’
5’-TGCAAGGGATTGTTCAAATG-3’
5’-AAGGCATAGAAAATGGGGAAA-3’

IL-6

β-actin

5’-AACTGGGACGACATGGAGAA -3’
5′-ATACCCCTCGTAGATGGGCA -3′

5′-AGATGGAGAAGGGCAGTTAG-3′
5′-GATTCGCAGCGCATCGCCTT-3′
5′-TCCAGTTGCCTTCTTGGGAC-3′
5′-GTACTCCAGAAGACCAGAGG-3′
5′-TGTGATGGTGGGAATGGGTCAG-3′
5′-TTTGATGTCACGCACGATTTCC-3′

2.4.5 MEASUREMENT OF TRANSEPITHELIAL ELECTRICAL RESISTANCE

45

Caco2 monolayer barrier function was evaluated by measuring the electrical
resistance and paracellular permeability. The transepithelial electrical resistance (TER)
of the filter-grown Caco2 monolayers was measured with an epithelial volt ohmmeter
(Millicell ERS; Millipore Company, Bedford, MA, USA). Electrical resistance was
recorded with three consecutive measurements after subtracting the resistance value of
the filters alone.

2.5

ANIMAL STUDIES TO EVALUATE EFFECTS OF EGCG ON MUCOSAL

INFLAMMATION
Animals used in the DSS colitis protocol consisted of C57/Bl6 mice ordered from
Jackson Laboratory. All aspects of the study were carried out under protocols approved
by the Institutional Animal Care and Use Committee (13.068M1). Mice were divided at
random into groups of 5 mice per cage under standard conditions for light/dark cycle,
temperature and humidity.

Mice received ad lib standard mouse chow during the

experiment. EGCG was added to the drinking water on a daily basis to avoid spillage
and contamination, as well as, monitor daily intake to determine whether any
discrepancies in dose occurred during the study.

2.5.1 DSS MODEL OF INTESTINAL INFLAMMATION
Groups of C57BL/6 mice (n=5) acclimatized for 5-7 days prior to initiating the
experimental protocol. Animals were then exposed to 2.5% DSS (experimental) or plain
drinking water (control) with or without EGCG at two doses (2 or 20 µg/mL) in their
drinking water. DSS control groups were exposed to 2.5% DSS only from days 1-9,
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while EGCG was given concurrently from days 1-9 as a preventative agent or after DSS
administration on days 9-16 as a treatment agent. Weights were taken daily to assess
colitis severity; in addition, endoscopies were completed on days 9 and 16. Mice were
sacrificed on day 17, and blood samples were collected. Colon lengths were measured,
and portions of intestinal tissue were collected and flash frozen in liquid nitrogen. All
samples were stored at -80oC for further analysis.

2.5.1.1 INDICATORS OF HEALTH
Daily weights were measured during the experimental protocol.

Mice

experiencing greater than 10% weight loss were evaluated twice daily, to look for
evidence of failure to thrive. If general appearance (including rough hair coat, hunched
posture, lethargy, or persistent recumbent position) developed in addition to 10% weight
loss, the animals were monitored on a daily basis by veterinary technicians. If an animal
lost more than 15% body weight, it was removed from its cage and placed into an
isolation cage with additional water sources, such as long sipper tubes or water gel. If
weight loss continued to 20%, or additional indicators of moribundity developed (such as
head tucked into abdomen, exudates around the eyes and/or nose, abnormal breathing,
difficulty with ambulation, decreased food and/or water intake, or self-mutilation), then
animals were euthanized.

2.5.1.2

MEASUREMENT

OF

COLONIC

ENDOSCOPY
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INFLAMMATION

BY

SERIAL

Prior to colonoscopy, mice were anesthetized using intraperitoneal injection of
ketamine/xylazine (100/10 mg/kg). The colonoscopy apparatus (Karl Storz, Tuttlingen,
Germany) consisted of a miniature endoscope (scope 1.9 mm diameter), a xenon light
source, a triple chip camera, and an air pump to achieve regulated inflation of the mouse
colon. After mice were adequately sedated, the colonoscope was lubricated with sterile
water then inserted under direct visualization into the rectum. The colonoscope was
advanced after obtaining a view of the colon lumen until the bowel was obstructed by
stool or the scope could not be advanced any further without impacting the wall of the
colon. The colonoscopic procedure was viewed on a color monitor and digitally recorded
for later viewing and archiving. Endoscopic scoring was performed in blinded fashion.
A score was assigned immediately after the colonoscopy. Mice were placed in clean
cages, which were then placed on a warming pad until movement was detected. Once
mice began purposeful movements, cages were replaced in the housing racks.

2.6 STATISTICAL ANALYSIS
Results for cytokine expression were calculated using the 2-ΔΔCT method.
Cytokine expression levels were represented as a percentage of the cytokine expression
of the control at baseline conditions (no LPS, no EGCG). Each figure represents four
individual experiments, each performed in triplicate, with results represented as mean ±
standard deviation (SD). Statistical significance of these data was determined by twoway ANOVA with Tukey’s Multiple Comparison test using Prism 6 for Mac software
(Prism, La Jolla CA).
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2.7

CLINICAL TRIAL EVALUATING EFFECT OF EGCG ON ULCERATIVE

COLITIS
An investigator initiated clinical trial was designed and submitted to the Food and
Drug Administration under Investigational New Drug application #74117. The clinical
protocol was submitted to the University of Louisville Institutional Review Board (IRB)
and approved for recruitment. All clinical trial activities were performed under a consent
form approved by the University of Louisville IRB (protocol # 390.95). The trial was
registered in clinicaltrials.gov under identifier NCT00718094. The trial was supported
by NIH grant 5K23DK073750.

2.7.1 STUDY DESIGN AND DEFINITION OF CLINICAL ENDPOINTS
A randomized, double-blinded, placebo controlled phase IIa pilot study was used
to evaluate EGCG in patients with ulcerative colitis. The primary objective of the study
was to evaluate the safety and efficacy of (-)-epigallocatechin-3-gallate (EGCG) in
patients with mildly to moderately active UC as determined by the UC Disease Activity
Index (UCDAI), a standard method of measuring disease activity (Sandborn, Tremaine et
al. 1997). Subjects were classified as responders if they experienced a drop in their
baseline UCDAI score by three or more points at day 56, or if they recorded an exit score
of < 2. Clinical remission was defined as a UCDAI score < 2 at day 56, with an
endoscopic sub-score of 1 or less. Finally, an important secondary endpoint examined the
impact of Polyphenon E® on quality of life (QOL), as determined by the Inflammatory
Bowel Disease Questionnaire (IBDQ). The IBDQ is a validated, IBD-specific indicator
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of QOL (Guyatt, Mitchell et al. 1989), and was used with permission from McMaster
University (Hamilton, Ontario).

2.7.2 SUBJECT SELECTION AND ETHICAL CONSIDERATIONS
Patients ≥ 18 years of age with mildly to moderately active disease (UCDAI score
≥ 4 and ≤ 10) were eligible for enrollment in the Institutional Review Board approved
protocol. Informed consent was obtained prior to the conduct of any study related
activity. Subjects had to have carried an endoscopically verified diagnosis of ulcerative
colitis extending beyond the rectum for at least three months. Subjects already taking 5ASA products were allowed to enter the study if they had been taking a stable dose for at
least four weeks. Subjects previously treated with 5-ASA but who were intolerant of that
therapy had to have been off 5-ASA therapies for at least two weeks prior to
randomization. Subjects with persistent UC symptoms, despite taking a stable dose of
immunomodulator therapy such as azathioprine (AZA) or 6-mercaptopurine (6-MP) for
eight weeks, were allowed to enter the study on their baseline medication dose. Subjects
currently taking corticosteroids, mycophenolate mofetil, methotrexate, cyclosporine,
tacrolimus, or sirolimus were not permitted to enter the study. Those with recent use had
to have undergone a four week washout period prior to randomization. Other exclusion
criteria consisted of:

(1) a positive stool sample for bacterial pathogens, ova and

parasites or Clostridium difficile toxin; (2) pregnancy or lactation; (3) documented human
immunodeficiency virus (HIV) infection; (4) signs or symptoms of severe progressive or
uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or
cerebrovascular disease; (5) abnormal baseline lab studies including a serum creatinine

50

level ≥ 1.5x upper limits of normal (ULN); total bilirubin, aspartate transaminase (AST)
or alanine aminotransferease (ALT) levels ≥ 2x ULN, or (6) concomitant, regular use of
non-steroidal anti-inflammatory agents.

2.7.3 DETERMINATION OF ELIGIBILITY AND SUBJECT ENROLLMENT
Each subject was consented and evaluated for eligibility. Patients fulfilling all
screening requirements were randomized in a double-blinded fashion according to a
random number generator compiled by a statistician not involved in the study. Subjects
were allocated to treatment or placebo in a 4:1 ratio (Figure 1A). Criteria for involuntary
withdrawal from the study included the occurrence of a serious adverse event considered
to be related to the study agent, or the presence of a UCDAI exceeding 10 at any visit.
No subject required termination. Subjects withdrawing from the study were registered as
non-responders.

2.7.4

MEASUREMENT OF CLINICAL ENDPOINTS OF EGCG SAFETY AND

EFFICACY
All subjects were evaluated on days 1, 14, 28, 56, and 70. UCDAI was obtained
on days 1 and 56 and the IBDQ was assessed on days 1, 14, 28, and 56. Safety labs
consisted of:

(a) complete blood count (CBC) with differential, (b) comprehensive

metabolic panel, and (c) stool studies, including stool culture for enteric pathogens,
Clostridium difficile toxin assay, and ova and parasite analysis.

Compliance was

evaluated by monthly pill counts ≥70%. Serial blood draws were assessed on day 1 and
day 56 to evaluate the pharmacokinetics of EGCG in UC patients.
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Finally, the

endoscopic response was evaluated by flexible sigmoidoscopy on days 0 and 56, to
complete UCDAI scoring.
Criteria for involuntary withdrawal from the study included the occurrence of a
serious adverse event that were considered to be related to the study agent, or the
presence of a UCDAI exceeding 10 at any visit.

2.7.5 SUBJECT RANDOMIZATION AND RATIONALE FOR CHOSEN DOSING
REGIMEN
Twenty subjects were randomized to one of two groups:

active therapy or

placebo. Of the 10 subjects enrolled into cohort I, those subjects randomized to active
therapy (low dose Polyphenon E®) ingested one Polyphenon E® capsule containing
200mg EGCG plus one identical appearing placebo, twice daily. Subjects randomized to
active therapy in cohort II received high dose Polyphenon E® (400mg EGCG BID). The
doses studied in this trial were determined during discussions with regulatory personnel
while negotiating an Investigational New Drug (IND) application. The doses agreed
upon were based on safety and pharmacokinetic data from the largest trial of green tea
polyphenol components to date, which demonstrated that the chosen doses would result
in an serum EGCG level that was immunologically active based on recent work on the
immunoregulatory effects of EGCG (Chow, Cai et al. 2003, Dryden, Fernandez-Botran et
al. 2011).

Subjects randomized to placebo in either cohort received two capsules

identical to Polyphenon E® twice daily. Subjects took the assigned study agent on days
1-56 (+/- 5 days), and underwent a physical exam and UCDAI calculation (including
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endoscopy) prior to drug administration (day 0) and after 56 days of study agent
exposure.
2.7.6 STATISTICAL ANALYSIS
Demographic information was compared between groups by χ2 for categorical
data and by unpaired t-test for continuous data. The percentage of subjects experiencing
a response by the UCDAI (> 3 point decrease) or entering remission (< 2 point total) was
compared between the aggregate subjects receiving Polyphenon E® or placebo by
Fischer’s exact test. All statistics were two-sided calculations with a significance level of
0.05 unless otherwise indicated. Calculations were performed with Prism 5 (GraphPad,
La Jolla, CA).
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CHAPTER 3

ROLE OF EGCG AS A PREVENTIVE AND THERAPEUTIC AGENT IN THE DSS
MODEL OF COLONIC INFLAMMATION

3.1 INTRODUCTION
Animal models of inflammation serve as useful tools for obtaining pre-clinical
information regarding the effects of a candidate therapy on inflammatory bowel disease.
A number of animal models of IBD exist, but one of the most commonly used is the
dextran sodium sulfate (DSS) model in mice. The DSS model of intestinal inflammation
most closely represents human ulcerative colitis (Okayasu, Hatakeyama S Fau - Yamada
et al.). This model depends on the oral administration of 40-50kDa DSS in drinking
water, but the exact mechanism is unknown. One recent investigation suggested that
colonic inflammation is mediated by dextran binding to dietary medium chain
triglycerides, with the resulting moiety fusing to colonocyte cell membranes (Laroui,
Ingersoll et al. 2012). Subsequent uptake into the cytoplasm triggers the release of
inflammatory cytokines. Unlike other models, the DSS model does not depend on the
adaptive immune system and can be used in RAG-/- and SCID mice to isolate the effect
on particular aspects of the immune response (Chassaing, Aitken et al. 2014). The model
is rapid and reproducible. We elected to use the DSS model to test orally administered
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EGCG to mimic the route of human administration, and to reproduce the mucosal uptake
of this compound, which likely results in different distribution patterns of the compound
in the body compared to other methods of administration, such as intraperitoneal
injection. During our investigation, we also elected to evaluate two different treatment
strategies, including early administration (mimicking a prophylactic approach) and late
administration (mimicking a traditional treatment approach for suppressing already
established colitis). In addition, two different doses were evaluated to determine whether
a dose dependent response existed.
Figure 6. Schema for EGCG
administration and endoscopy.
Animals were divided into
groups of 5. Control animals
provided baseline data for
comparison.
DSS treated
animals provided a positive
control.
Animals receiving
EGCG had either low dose (2
µg/ml) or high dose (20 µg/ml)
EGCG administered from day 0
through day 9 in the preventative
group, or days 9-14 to animals in
the treatment group.
3.2 RESULTS

3.2.1 EGCG REDUCES WEIGHT LOSS AND IMPROVES SURVIVAL IN THE
SETTING OF DSS ADMINISTRATION
The initial manifestation of inflammation in the DSS model is weight loss, which
begins around day 3 and bottoms out around day 7. DSS is typically administered at
concentrations of 3-5%, with higher concentrations inducing greater weight loss and
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severity of colitis. During dose optimization, we found that a concentration of 2.5% for 9
days provided the maximal differentiation of differences between treatment groups when
using wild type C57/Bl6 animals. When using genetically modified animals that are
susceptible to colitis or when another mucosal irritant such as ethanol is added to the diet,
the concentration of DSS must be reduced to the range of 1-2%. In our investigation of
EGCG in the DSS model, we tracked weights and viability on a daily basis. If an
animal’s weight dropped 15% from baseline, we housed the animal separately and
provided additional sources of hydration. If an animal dropped more than 20% below
baseline, it was euthanized to prevent unnecessary pain and suffering.

Percent survival
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2µg/mL protect
2µg/mL treat
20µg/mL protect
20µg/mL treat
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adjacent figure (figure 7),
mice treated with DSS
alone

40
30

As seen in the

Control

90

0

5

10

had

the

worst

survival rates, with up to

15

Day of protocol

Figure 7. Mortality rates per treatment arm. All EGCG
treatment arms experienced lower mortality rates than the
DSS treated animals.

60% of animals dying or
being euthanized due to

excessive weight loss. The best survival rates occurred in mice pre-treated with the
lowest dose of EGCG initiated as a preventative agent prior to the onset of inflammation.
Other treatment groups all experienced some loss of animals, but in significantly fewer
numbers than DSS alone. The addition of EGCG beginning at day 9 appears to have had
a substantial effect of rescuing the mice exposed to the full course of DSS without a
protective agent. Otherwise, we should have seen similar mortality rates compared to the
DSS control animals.
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In regard to weight loss, the animals receiving the lowest dose of EGCG in
drinking water under the treatment protocol actually experienced the least amount of lost
weight (figure 8). With the exception of the 20 µg/ml treatment group, EGCG treated
groups of mice had intermediate levels of weight loss. The degree of weight lost by the

% Change from baseline

highest dose treatment
110

*
100

*

*

Control
2µg/mL protect
2µg/mL treat
20µg/mL protect
20µg/mL treat

*

90

80

group tracked along with
the DSS control group.
The animals in the high
dose treatment group,

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Treatment day

Figure 8. Weight change from baseline. Animals were
weighed on a daily basis. The percentage of weight
change from baseline is indicated above for each
individual treatment group and DSS controls.

compared

to

the

protective groups, did
not rebound faster than

the DSS control group. This observation could be related to changes in taste of the water
caused by the higher dose of EGCG, leading to decreased water intake overall, or it could
be related to an unknown impact on the inflammatory process, such as inducing increased
apoptosis in intestinal epithelial cells. The latter explanation, however, is unlikely based
on the fact that the endoscopic and histologic evaluations of colitis in the high dose
treatment group were essentially no different from low dose treatment or either of the
preventative groups (see below).

3.2.2 EGCG IMPROVES COLITIS SCORE AS DETERMINED BY SERIAL MURINE
COLONOSCOPY
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Murine colonoscopy has evolved into a useful tool for monitoring the evolution of
mucosal inflammation.

Initially described in 2002 (Huang, Carter et al. 2002), the

technique has been rapidly developed to include objective measures of both inflammation
and tumor burden (Becker, Fantini et al. 2005). These techniques apply particularly well
to the DSS model of colitis or azoxymethane/DSS inflammation driven colon tumor
model, due to the fact that the distal colon is most heavily involved with disease burden
in both models. For the purposes our investigation, we performed serial endoscopies to
monitor the maximal onset and subsequent resolution of colitis. This allowed us to better
estimate the timing of onset and resolution of colitis to determine differences between the
prophylactic administration compared to the reactionary treatment arms. The following
scoring criteria were used to measure endoscopic disease severity in a blinded fashion by
the endoscopist:
EIS Scoring Criteria

Table 3. Scoring criteria for colitis severity. Colitis scores are determined by
endoscopy with each criterion being assigned a value between 0 - 3, with 3 being the
most severe. Total severity scores are calculated by adding all five sub-scores, for a
possible maximum score of 15 (Becker, Fantini et al. 2005).
As seen in figure 9, below, the groups receiving prophylactic therapy prior to the onset
of inflammatory symptoms fared significantly better than “treatment” groups.

The

higher dose provided greater protection against inflammation. All groups receiving
EGCG had significantly lower endoscopic scores of severity compared to animals
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treated with DSS only by the second
endoscopic

evaluation.

When

considering the day 16 data, all EGCG
treatment groups had significantly less
inflammation,

with

no

significant

differences between the EGCG treated
groups, although numerically, the antiinflammatory effect appeared to impart a
stronger treatment effect as evidenced by
lower endoscopic scores in the animals
Figure 9. Effect of EGCG on mucosal
findings and colitis severity scores.
Animals were evaluated by endoscopy. (A)
top, EIS scores on days 9 and 16 were
determined via endoscopy, using Table 1
for analysis of findings. Data shown include
mean and standard deviation (mean ± SD)
of 3-5 mice. Statistical significance
(p<0.01) was indicated by asterisks (**) and
determined by ANOVA and Dunett’s
Multiple Comparison test. (B) bottom left,
endoscopy of mouse with DSS-induced
colitis. (C) bottom right, endoscopy of
mouse treated with EGCG.

receiving EGCG right up to two days
before

the

assessment

second
than

the

endoscopic
preventative

treatment groups.
3.2.3

EGCG

INFLAMMATORY

REDUCES
CYTOKINE

PRODUCTION AS DETERMINED
BY ELISA AND RT-PCR

Next, we evaluated the immunologic contributors to inflammation underpinning
the endoscopic results seen in the previous section. Cytokines were evaluated in serum
samples taken from the portal vein at the time of sacrifice and RT-PCR for various
cytokines of interest was performed on homogenates of the distal colon from individual
animals from each group.

Each analysis consists of readings from 3-4 individual
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Figure 10. Cytokine
analysis of portal vein
Prevention
plasma samples from animals in the
prevention group.
A panel of Th1
inflammatory cytokines were were
analyzed by multi-bead ELISA (left
column) or by PT-PCR (right column).
Animals received either DSS alone or in
combination with low dose or high dose
EGCG. RT-PCR compared to DSS alone
as baseline. Statistical significance of
p<0.001 indicated by ****, as determined
by ANOVA and Dunett’s Multiple
Comparison test. Data are expressed as
mean + SD of four independent
experiments.
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Figure 11. Cytokine
analysis of portal vein
plasma samples from animals in the
treatment group.
A panel of Th1
inflammatory cytokines were were
analyzed by multi-bead ELISA (left
column) or by PT-PCR (right column).
Animals received either DSS alone or in
combination with low dose or high dose
EGCG. RT-PCR compared to DSS alone
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Comparison test. Data are expressed as
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3.2.4 TRANSCRIPTION OF SELECT
BARRIER RELATED PROTEINS AS
DETERMINED BY WESTERN BLOT
AND RT-PCR
Given the tight relationship of
inflammation and enterocyte exposure to
inflammatory cytokines and TJ protein
composition, we next proceeded to
evaluate the change of various TJ
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proteins based on the relative levels of message and proteins in relation to the change in
cytokine production.
A.

B.

Figure 12. Tight junction protein content from colonic epithelium. Colonic epithelial
cells were isolated from mouse colons, lysed and harvested for protein analysis.
Western blot analysis was carried for TJ proteins of interest. (A). Individual bands
from Western blot of colonic cells from animals treated with EGCG 20 µg/ml. (B).
Semi-quantitative densitometry analysis of WB bands using ImageJ analysis software.
Statistically significant (p<0.001) increases are indicated by *** and were determined
by ANOVA and Bonferroni’s Multiple Comparison test.

3.3 DISCUSSION
The DSS model of colitis provides a useful model for evaluating novel therapies
for IBD, with a particular relevance to UC. It provides an opportunity to evaluate the
impact of a target therapy on several different aspects of the inflammation process. In
our evaluation of EGCG as an anti-inflammatory therapy for DSS colitis, we focused on
the effects of this topically active therapy on the mucosal interface. EGCG positively
affected the general indicators of inflammation such as weight loss and mortality at both
administered doses, without a clear-cut benefit of one over the other from those
endpoints. Based on the fact that both active as well as preventative therapies are needed
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in the clinical arena, we added a preventative arm to our evaluation, similar to how
EGCG might be used to suppress the onset of inflammation to prevent post-operative
recurrence of Crohn’s disease. This is a particularly important unmet need in the field of
IBD therapeutics, as the only form of medical therapy that has shown to be effective in
preventing post-operative recurrence is the anti-TNF Ab class of therapeutics (Cottone,
Orlando et al. 2003, Regueiro, Schraut et al. 2009, Carla-Moreau, Paul et al. 2015). The
problem with surgical resection of Crohn’s disease has always been the fact that Crohn’s
disease recurs rather quickly. Within 12 months after surgery, 70-90% of patients will
have endoscopic recurrence of disease (Olaison, Smedh et al. 1992) and up to 30% will
have recurrent clinical symptoms (Rutgeerts, Geboes et al. 1990). Because of the high
cost ($777,732.00 per quality adjusted life year) and significant risks associated with
long-term administration of anti-TNF therapy to prevent the possibility of a recurrence
(Ananthakrishnan, Hur et al. 2011), it seems obvious that this indication should be a
priority target for new drug development. The animals receiving preventative therapy
were the only animals to have a statistically significantly lower degree of inflammation
endoscopically. There appeared to be a dose dependent relationship to the endoscopic
severity, such that the high dose of EGCG provided greater protection against DSS colitis
than the low dose.

We feel that the endoscopic evaluation of animals provides a

clinically relevant evaluation of drug efficacy that observational scales such as the colitis
severity index (based on a composite measurement of whether stool is loose or contains
blood) cannot provide. The animals treated with preventative doses of EGCG also had
essentially no colitis seen on microscopic evaluation of their colonic tissue taken at the
end of the study. Additional animals euthanized at the mid-point of the study could have
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provided a more definitive assessment of microscopic severity, but the mid-point
endoscopic evaluation likely provides an equivalent surrogate without having to increase
the number of mice studied.

Most recently approved therapies for IBD consist of parenterally administered
immune modulating substances, mainly based on monoclonal antibody constructs
targeting specific aspects of systemic immune cells. These therapies generally provide
systemic anti-inflammatory effects, along with systemic immunosuppression. In fact,
systemic infections constitute the largest number of serious side effects of most current
therapies. One recently approved therapy, vedolizumab, targets the α4β7 integrin to
provide a relatively GI specific immunotherapy. This approach has limited the incidence
of infectious complications to very low levels (Feagan, Rutgeerts et al. 2013). However,
monoclonal antibody therapy incurs high costs and still puts patients at risk for
complications such as infusion reactions or other infusion related complications. EGCG,
on the other hand, has been implicated in reducing inflammation, but with few attendant
“immunosuppressive” side effects such as those induced by interleukin-10 upregulation
(Katiyar, Challa A Fau - McCormick et al.). This makes it an attractive therapy for IBD,
as all of the current IBD therapies with the exception of 5-aminosalicylic acid (ASA)
induce some degree of immune suppression and subsequently increase the risk of
systemic infections.

Based on our analysis of the portal vein and colonic mucosal cytokine profiles
from the DSS colitis study, we did see a significant anti-inflammatory effect from the
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administration of EGCG. Although the systemic absorption of EGCG from the GI tract
is poor, data from human pharmacokinetic studies suggest that circulating levels could
reach the threshold for biologic activities. In order to understand the effects of systemic
EGCG on circulating immune cells, we next performed a survey of the impact that
EGCG could have on specific components of the immune system that play a role in IBD.
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CHAPTER 4

EGCG IMPACTS PRODUCTION OF IMPORTANT CYTOKINE
INVOLVED IN INTESTINAL INFLAMMATION

4.1 INTRODUCTION: PERIPHERAL IMMUNE CELLS
Peripheral blood monocytes (PBMCs) provide a broad-based window into the
immune status of a patient under evaluation.

The PBMC population consists of a

heterogenous collection of immune cells collected from the systemic circulation. This
pool of immune cells reflects the general immune tone of the individual being examined
as well as represents a population of cells that can readily be recruited to assist in the
event of a immunonological crisis. These cells often exist in a precursor state that differs
from the tissue resident state, such as the CD14+ bone marrow derived monocyte that is
recruited into inflamed intestinal tissue under the guidance of the interaction of interferon
gamma-induced protein (IP)10/chemokine receptor CXCR3 (Grimm, Pullman et al.
1995). These antigen presenting, cytokine producing monocytes rapidly evolve into
purely phagocytic resident macrophages within days of migrating to the intestinal mucosa
and cannot be stimulated to produce cytokines even with prolonged stimulation with
bacterial antigens (Smith, Smythies et al. 2011).
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Samples obtained from IBD patients participating in our studies contained
monocytes and both effector and naïve T cells. Although we did not have before and
after samples from patients receiving oral EGCG, we felt that it would be valuable to
study the effects of pharmacologically relevant amounts of EGCG spiked into samples of
immune cells harvested from IBD patients. Analysis of these cells would allow us to
model the effect of systemically available EGCG on circulating immune cell cytokine
production. Although many studies on patient samples inspect only a narrow range of
cytokines, recent evidence has linked a suppressive effect on many of the regulatory
pathways that control Th1-type effector cytokine protein production and secretion. We
elected to begin our evaluation of EGCG as an IBD therapeutic useful for human disease
by performing a survey of the effects of EGCG on the secretion of Th1 type cytokines
from an assortment of the immune cells that play a significant role in IBD.

4.2 RESULTS
We found that EGCG produced a significant anti-inflammatory effect on all the
immune cell populations that were studied.

Interestingly, immune cells from IBD

patients secreted much higher levels of cytokines in general when at rest in the growth
medium compared to cells from normal volunteers. Upon stimulation with LPS or other
appropriate immune cell activators, cells from IBD patients produced enormous amounts
of cytokines compared to stimulated cells from normal volunteers. The effects from
human plasma containing a mixture of immune cells, plus individual populations
obtained by magnetic bead separation were probed more closely.
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4.2.1 EFFECTS OF EGCG ON PRIMARY IMMUNE CELLS
Primary immune cells provide a more relevant platform for testing the effects of a
potential anti-inflammatory therapy than cell lines. Cell lines are generally derived from
either hematologic or solid organ malignancies, and may not represent a true
physiological response to therapy. Cytokine responses or signaling pathways of interest
may be disrupted by mutations that led to the development of the tumor in the first place.
Primary immune cells reflect a more “normal” state of affairs, and generally tolerate
short-term culture well. This makes time course evaluation possible. In vitro analysis
also allows cells to be stimulated or inhibited under various conditions or tested against
multiple concentrations of the potential therapeutic. We used primary immune cells to
evaluate the impact of EGCG on cytokine production and gain insight into potential
mechanism.

4.2.1.1 EFFECTS OF EGCG ON IMMUNE CELLS FROM IBD PATIENTS BY EX
VIVO PLASMA CYTOKINE ASSAY
Perpetuation of the immune response in IBD comes from continuous recruitment
of immune cells from the systemic circulation to replenish aging or damaged resident
immune cells. In most disorders, immune modulating therapies must target circulating
immune cells, as it might be difficult to get drug to the affected tissue, especially in
situations like central nervous problems (due to the blood brain barrier), bone, or active
infection. Other tissues are quite amenable to drug delivery by oral ingestion, such as the
intestinal mucosa, due to the fact that the drug must cross the gastrointestinal
tract/luminal interface prior to absorption. In order to evaluate the potential systemic
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effects of EGCG on circulating immune cells, we utilized a whole blood ex vivo model
established to assess potential effects of anti-cytokine therapies. We and others have
used this method to effectively screen candidate compounds for anti-inflammatory
activity (McClain, Barve et al. 1998, Stadlbauer, Mookerjee et al. 2008).

Figure 13. Ex vivo cytokine testing. EGCG suppresses the ability of LPS to elicit
inflammatory cytokine production by peripheral blood leukocytes in an ex vivo
model developed to screen for anti-inflammatory activity of potential therapeutic
agents. Plasma was obtained by centrifugation of 5 ml of the whole blood
immediately after being drawn from IBD patients and normal healthy individuals.
All plasma samples were individually incubated in the presence of varying
concentrations of EGCG (0-10 µg/ml) at 370C and 5% CO2 for 24 hours.
Samples were stimulated overnight with lipopolysaccharide 10 ng/ml. All
experiments were controlled with unstimulated cells.

As seen in figure 13, EGCG induced a significant reduction in ex vivo cytokine
production in LPS-stimulated samples from IBD patients. We initially chose a small
number of type 1, IBD-related cytokines for this ex vivo testing (upper row). Samples
spiked with LPS demonstrated a sharp increase in all tested cytokines. Samples that were
initially stimulated with LPS then co-incubated with EGCG saw levels of TNF-α and
IFN-γ suppressed, nearly to their pre-stimulated baselines. In the case of IL-1β, EGCG
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suppressed cytokine production to a level below unstimulated baseline. In this model,
the maximal suppressive effect occurred at a concentration of 10 µg/ml, which is
clinically feasible based on available pharmacologic data (Chow, Cai et al. 2003). Given
the positive results from the whole blood ex-vivo assay, we opted to evaluate the effect on
other important Th1 effector cytokines that play a significant role in IBD.

In all

instances, there appeared to be a suppressive effect from EGCG on the production of
these inflammatory cytokines. IL-12 seemed to be least affected, but reductions in IL-23
and IL-17A were profound in the plasma samples from IBD patients. The results of this
experiment suggest that peripheral exposure to pharmacologically feasible levels of
circulating EGCG might significantly dampen LPS-mediated activation pathways of
immune cells while in the intravascular compartment, validating the potential for EGCG
as a systemic therapy.

4.2.1.2 CD14+ MONOCYTES
Since CD14+ monocytes play such a large role in the innate immune response to
inflammation and infection, we desired to know whether EGCG could suppress cytokine
secretion in their pre-migratory state. This is pertinent to stemming the inflammation
from IBD, as newly recruited CD14+ monocytes can act as antigen presenting cells
during acute inflammation, and serve as chief sources of Th1 type cytokines in the early
phase of an immune response (Smith, Smythies et al. 2011). They are continuously
replenished through a variety of mechanisms, including chemokine receptor
(CXC3R)1/fractalkine binding or interaction the gut-specific α4β7 integrin and the cell
adhesion molecule mucosal addressin cell-adhesion molecule-1 (MadCAM-1) (Waddell,
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Ahrens R Fau - Steinbrecher et al. , Zigmond and Jung , Schippers, Muschaweck et al.
2015). Under homeostatic conditions of the non-inflamed bowel, these cells evolve
under the influence of IL-10 into tissue resident macrophages which no longer contribute
to the cytokine storm (Zigmond, Bernshtein et al.). However, EGCG could provide a
suppressive influence on IBD by dampening the production of cytokine responses from
newly arriving monocytes within the lamina propria.

CD14+ macrophages from both IBD patients and normal volunteers were
isolated from the buffy coat of peripheral blood samples by magnetic bead technology.
LPS was added to the culture medium in designated arms of the experiment to stimulate
cells during overnight incubation. Next, cells were incubated in the presence of EGCG
(0-10 µg/ml) at 37oC and 5% CO2 for 24 hours. Read outs from stimulated cells +/EGCG were compared to basal cytokine secretion from un-stimulated cells. Additional
testing to determine the impact of EGCG on unstimulated cells demonstrated similar, but
lesser, impacts of EGCG (data not shown).
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Figure 14. CD14 monocytes exposed to multiple concentrations of EGCG. A panel of
Th1 cytokines were analyzed from supernatant taken from CD14+ monocyte culture.
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As in the case of the cell-containing serum samples from the previous section,
individual cultures of CD14+ monocytes also demonstrated significant reductions in
inflammatory cytokine secretion. Again, the most vigorous response to LPS was seen in
IBD patient monocytes, as baseline cytokine secretion in unstimulated cells occurred at
the least an order of magnitude higher than in normal cells, especially for the type 1
cytokines such as interferon-γ, tumor necrosis factor-α, and IL-1β.

IBD cells also

expressed higher levels of the effector cytokines IL-12, IL-23 and IL-17 compared to
normal cells, but not to the same extent. LPS-induced rises in cytokine production/
secretion followed similar patterns, although the response to LPS produced less variance
than in the plasma samples.

This experiment demonstrated that EGCG effectively

specifically dampens the robust monocyte secretory response found at baseline in
circulating monocytes from IBD patients, while the effect on LPS-stimulated cells
predicts a suppressive effect once the monocytes migrate into inflamed mucosa and
encounter antigenic stimulation.

4.2.1.3 CD3+CD45+RO T CELLS
Although monocytes enter the inflamed tissue in a less mature state, effector T
cells homing to the intestinal tract have generally matured through an antigen-specific
activation process in the mesenteric lymph node. Circulating activated effector T cells enter
the intestinal tissue in a controlled manner under the guidance of intestinal specific cell
adhesion molecules that interact with the intestine homing specific integrin combination
α4β7 (Erle, Briskin et al. 1994). Although the T cell population expressing this integrin
heterodimer makes up only about 1-3% of circulating lymphocytes, its contribution to the

72

dysregulated adaptive immune response in the inflamed GI tract is responsible for causing a
considerable amount of the injury in IBD (Arihiro, Ohtani et al. 2002). In order to evaluate
the ability of EGCG to impact the Th1 effector T cell population’s contribution to intestinal
inflammation, we isolated CD3+CD45+RO T cells and activated them by CD3/CD28
antibodies as detailed in chapter 2: methods section.
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Figure 15. Effect of EGCG on activated effector T cells. CD3+CD45+RO T cells were
separated by magnetic bead technology from peripheral blood monocytes obtained
RO
from the buffy coat of normal volunteers vs IBD patients. The rate of baseline unstimulated cytokines production ranges from 2-4 x higher in IBD patients than in
samples from volunteers.
The resting pattern of cytokine secretion from normal volunteer and IBD patient
effector T lymphocytes exhibited a pattern similar to that of serum and isolated CD14+
monocytes. Interestingly, IL-6 secretion from normal samples were 50% of the baseline
from IBD patients. This is the lowest ratio of normal to IBD resting cytokine secretion seen
among the tested cytokines. As in the other examples, stimulation of the cells produced a
much greater rise when comparing IBD patients to normal patients. The only exception was
IL-6 secretion, where stimulated RO T cells from normal samples secreted as much IL-6 as
those from IBD samples. This suggests that T cells do not acquire a “primed” state for IL-6
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as they do for other inflammatory cytokines. These data also demonstrate that EGCG
produces a dose dependent reduction for a variety of inflammatory cytokines from activated
effector T cells. This should prove to be beneficial for control of inflammatory bowel
disease, as infiltrating T cells provide such a large contribution to the chronic inflammation
of IBD.

4.2.2.3

SUPPRESSION

OF

MONOCYTE

INFLAMMATORY

CYTOKINE

TRANSCRIPTS BY EGCG AS DETERMINED BY RT-PCR
In order to ensure that loss of cytokine production was not simply due to
inactivity of cells or loss of cells due to apoptosis under culture conditions, we evaluated the
production of mRNA transcripts by RT-PCR. Although mRNA was performed for all
analyzed cytokines, the results for the prototypical type 1 cytokines have been presented

100

****
****

NS

****
****

****
****

NS

****
****

NS

80
60

NS

40
20
0

C

C+LPS

IBD

IBD+LPS

0 µg/ml EGCG
5 µg/ml EGCG
10 µg/ml EGCG

C.
120
100

NS

***

NS

****
**
**

****
**
**

80

****
****
****

60
40
20
0

C

C+LPS

IBD

IBD+LPS

Suppression of TNF-α mRNA from baseline

B.
120

Suppression of IFN-γ mRNA from baseline

A.

Suppression of IL-1β mRNA from baseline

below in figure 16.

120

0 µg/ml EGCG
5 µg/ml EGCG 100
10 µg/ml EGCG 80

***
****
**

****
****
***

****
****

****
****

****

0 µg/ml EGCG
5 µg/ml EGCG
10 µg/ml EGCG

****

60
40
20
0

C

C+LPS

IBD

IBD+LPS

Figure 16. Effects of EGCG on selected cytokine message from stimulated CD14+
monocytes. Stimulated CD14+ monocytes were tested for the expression of (A) IL-1β,
(B) TNF-α, and (C) IFN-γ pro-inflammatory cytokine messages after exposure to EGCG
(0-10 µg/ml). Data are expressed as mean + SD of four independent experiments.
****P<0.0001; ***P<0.001; **P<0.01; NS = not significant. No change was seen in
RNA expression of these three TJ cytokines when CD4+CD45+RA T cells were evaluated
(data not shown).
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Cytokine suppression by EGCG was confirmed by RT-PCR on cDNA from cell
pellets isolated after culture of isolated immune cells (figure 16). In the case of all three
cytokines examined, the strongest suppression on mRNA message was seen in immune
cells from stimulated IBD subjects. In most cases, there were no significant differences
between EGCG 5 or 10 µg/ml doses, while the mRNA transcripts were sometimes
numerically greater at higher doses of EGCG. This did not correspond to cytokine
production in supernatant, suggesting that some cytokine production in response to LPS
may have been release of preformed intracellular sources. This would especially apply to
IL-1β, a cytokine that is made as a pro-cytokine and relies on caspase-1 cleavage to
achieve its secretory form (figure 3).

4.3 EFFECT OF EGCG ON TRANSCRIPTION FACTORS IMPORTANT TO THE
GENERATION OF EPITHELIAL INITIATION OF INNATE IMMUNE RESPONSE
The LPS induced upregulation of cytokine production is generally related to the
activation of various signaling pathways associated with TLR-2 or TLR-4 activation in
the case of Th1 cytokines. LPS activated CD14+ monocytes can also stimulate T cell
activation and even Th17 differentiation within inflamed intestinal tissues (Bogunovic,
Ginhoux et al. 2009, Shaw, Kamada et al. 2012). Intestinal epithelial cells also possess
the ability to differentiate between pathogenic and commensal bacterial antigens and
tailor cytokine secretion based on environmental cues (Campeau, Salim et al. 2012).
Furthermore, many sources from the oncology literature have documented the ability of
EGCG to influence a large number of signaling and cell differentiation pathways. Since
the intestinal epithelial cell is really the first cell line in the body to interact with EGCG,
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we decided to evaluate the impact of EGCG on intestinal epithelial cytokine secretion
and cell signaling pathways that are important for promoting tolerance in the intestinal
immune response. IECs secrete a variety of cytokines (Li, Seth et al. 1998, Lyu and Park
2009). Given reports that EGCG suppresses STAT3 and enhances suppressor of cytokine
signaling (SOCS) 3 (Sharma, Shankar et al. 2014, Yang, Lee et al. 2014), we chose to
evaluate its effects this important cytokine regulatory pathway in Caco2 cells.
Table 4. Effects of EGCG on selected signaling pathways.
Cytoplasmic Extract of Caco-2
Transcription Factor
No LPS
(1) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)
(2) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)
(4) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)

STAT3
100.00

ROR-γt
100.00

SOCS3
100.00

247.17±6.5
106.30±8.2
104.56±1.5

175.06±5.3
95.69±6.2
102.78±1.8

102.34±3.4
115.34±6.7
121.56±11.6

325.33±1.7
294.49±5.9
282.56±4.4

183.84±5.7
146.89±6.3
138.29±6.6

119.45±6.9
132.67±7.0
140.48±4.71

237.94±5.4
135.37±6.7
133.06± 4.8

188.45±3.6
138.67±4.6
142.78±6.3

125.89±5.6
144.47±4.9
148.56±73.5

Nuclear Extract of Caco-2
Transcriptional Factor
No LPS
(1) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)
(2) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)
(4) Hour Incubation
+ LPS only (10ng/mL)
+ LPS & EGCG (5µg/mL)
+ LPS & EGCG (10µg/mL)

STAT3
100.00%

ROR-γt
100.00%

123.53±3.4
127.75±5.6
125.89±6.2

111.26±4.7
39.13±5.1
38.78±2.3

140.87±5.2
138.98±4.3
136.56±2.4

129.09±5.4
116.80±3.7
112.67±5.6

116.77±5.7
37.34±6.3
36.89±6.6

151.56±6.8
155.45±6.9
158.89±4.6

139.45±5.4
109.89±6.7
103.00± 8.2

125.89±3.6
34.67±4.6
35.78±6.3

148.45±5.5
152.56±4.3
151.78±7.3
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SOCS3
100.00%

It has been well documented that IL-6 and IL-23 are common activators of STAT3
(Takeda, Kaisho et al. 1998, Cho, Kang et al. 2006). STAT3 then activates RORγt, an
integral step in Th17 polarization of naïve T cells undergoing immune activation (Yang,
Panopoulos et al. 2007). As seen in the table above, during our investigation into the
signaling processes in Caco2 cells, EGCG substantially affected STAT3.

Though

STAT3 signaling is typically ascribed to IL-6, the administration of LPS to our Caco2
cultures at 80% confluence initiated cytokine secretion and STAT3 activation, but at
100% confluence, no STAT3 activation occurred in response to LPS stimulation (data not
shown). STAT3 signaling was attenuated moderately in the cytoplasm, both suppressing
as well as prolonging the time to maximal activation. EGCG had a mild attenuating
effect on STAT3 translocation to the nucleus. The largest impact, however, occurred on
RORγt. The cytoplasmic levels of RORγt decreased by approximately 50%, while the
nuclear translocation of RORγt decreased by over 70% compared to non-treated cells.
Our findings also correlated with others that EGCG administration modestly enhanced
the upregulation of SOCS3.

4.3.1

CYTOKINE SECRETION BY IECs, AN IMPORTANT ORGAN OF THE

INTESTINAL IMMUNE RESPONSE
The intestinal epithelium cell is a multifunctional workhorse capable of
maintaining a barrier protecting the sensitive immune cells located below the barrier in
the lamina propria as well as influencing the immune system to promote pathogen
destruction while avoiding uncontrolled inflammation. IECs have been shown to secrete
a variety of cytokines, chemokines and immune regulatory proteins such as thymic
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stromal lymphopoietin (TSLP) (Rescigno 2014). IL-17, IL-23 secretion induced by LPS
in human colon cancer cell lines HT29 and T84 (Paolillo, Carratelli et al. 2009, Ghadimi,
Helwig et al. 2012), while IL-1α, IL-6, MCP-1, IL-23 secreted by Caco-2 cell line
(Mascia, Maina et al. 2010). In all instances, LPS provides a strong trigger for signaling
cytokine release, initiating secretion of greater amounts of cytokines than co-culture
model, with basolateral exposure leading to higher levels than apical (Ghadimi, Helwig et
al. 2012). We embarked on a survey of the type 1 and type 2 cytokines that could be
produced by Caco-2 cells, since primary human epithelial cells pose several difficulties
for long-term culture that we used to investigate certain aspects of cell signaling during
time course experiments.
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Figure 17. Survey of cytokines produced by Caco2 cells after LPS exposure The effects
of two concentrations of EGCG were evaluated in this study. Cells were exposed to 10
ng/ml LPS or cultured in medium alone for three hours. EGCG was added at various
concentrations for an overnight exposure.
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As seen in the figure above (figure 17), a variety of cytokines are produced by Caco2
cells at baseline. Significant upregulation of several cytokines occurred after exposure to
LPS. EGCG typically suppressed the cytokine secretion down to basal rates, or even
below unstimulated levels in the case of IL-33. These findings suggest that EGCG
provides a broad-based suppressive effect on intestinal epithelial cell cytokine secretion.
In most cases, the mRNA transcripts mirrored cytokine protein production (data not
shown).

4.3.3

EGCG SUPPRESSION OF PRE-FORMED, PRO-CYTOKINE SECRETION

REQUIRES EXPOSURE TO LPS
Data from our current work and others suggest that EGCG can suppress NF-κB
induced cytokine transcripts dramatically, supporting the theory that EGCG is exerting an
effect on inflammation by inhibiting the nuclear signaling effects of

NF-κB.

A

suppressive effect of EGCG also occurs in the case of IL-1β, but the degree of
suppression cannot be accounted for only by NF-κB inhibition. Interestingly, the cells
from colitis subjects experienced significantly higher rates of reduction from baseline
than unstimulated cells. IL-1β contained in the cytoplasm is not readily secreted into the
surrounding environment, due to the fact that it is translated into a pro-form of IL-1β that
requires cleavage to its active form prior to secretion (Lopez-Castejon and Brough 2011).
So, relatively little IL-1β is secreted unless stimulatory signals are received through the
binding of IL-1β to its cognate IL-1receptor with or without ATP, or through TLR
signaling.

Downstream signaling molecules lead to inflammasome activation and

subsequent cleavage of pro-IL1-β to its active form (Lamkanfi, Kanneganti et al. 2007).
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The inflammasome is a multiunit construct that comes together when an appropriate
intracellular signaling mechanism is activated (Hsu, Ali et al. 2008). This leads to
Caspase-1 activation. Caspase-1 cleaves pro-IL-1β, pro-IL-18, and pro-IL-33. Based on
that fact, we decided to evaluate the effects of EGCG on the three pro-cytokines to see if
there was a class effect against them.
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Figure 18. Three pro-cytokines need exposure to LPS prior to secretion. In order to
activate caspase-1, LPS must be added to the medium. LPS activates inflammasome
dependent cleavage of the pro-cytokines into an active form for secretion. Cells were
incubated with EGCG overnight, then exposed to LPS for three hours prior to
collecting supernatants.
The data detailed in figure 18 demonstrates that EGCG likely provides a dual
mechanism for suppressing inflammatory cytokine secretion. Based on the effects on
IFN-γ, TNF-α, IL-12 and -23, EGCG is conferring a suppressive effect on NF-κB
mediated cytokine modulation. This could also be providing an effect on pro-IL-1β
production as well, but the suppression seen in figure 18 likely represents a direct
suppression of caspase-1 mediated pro-cytokine cleavage under the effects of the
inflammasome. The culmination of these effects should play well with desire to treat
IBD patients with an effective anti-inflammatory agent that works well at the
microbial/intestinal interface.

4.4 DISCUSSION
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Experimental evidence demonstrates that EGCG effectively suppresses intestinal
epithelial cell secretion of cytokines. Likely happens due to inhibition of signaling
factors as in table 4, but also appears to inhibit cleavage of pro-form into active form via
caspase-1 activation as seen in figure 18. We continue to explore the direct activity on
caspase-1 as part of our ongoing efforts to characterize the immune effects of EGCG on
IBD.

Again, the potential impact of a luminally active agent is relatively

uncharacterized. While most developments in the field of IBD therapeutics deal with
systemic treatments to suppress the systemic immune system, with hopes of creating the
desired anti-inflammatory effect on the intestinal inflammation associated with IBD, the
promise of effective luminal therapy is great.

Clinical trial endpoints generally examine the change in clinical parameters over
time based on the response to treatment or placebo. Now, many new trials have begun to
embrace the concept of mucosal healing to evaluate the effect of newer, more focused
therapies for IBD by including a measurement of endoscopic disease severity before and
after treatment. Again, this attempts to answer the question of whether bystander healing
of the mucosa occurs as the systemic immune effect of the medication takes effect, but
unfortunately, methods for addressing the impact of therapy on the barrier function are
essentially non-existent. This is problematic in many ways, as the adaptive immune
response has become almost the sole focus for explaining the pathophysiology of IBD,
but not all patient symptoms can be explained by infiltrations of adaptive T cells and loss
of regulatory T cells (Seiderer, Elben et al. 2008). Infiltrative reactions by the adaptive
immune compartment generally take days to weeks to initiate and resolve, which does not
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exactly mirror the pattern of complaints voiced by IBD patients. Rather, patients often
complain of short-lived “flares” that are most often attributed to irritable bowel
syndrome, but this gives the patient two diagnoses rather than just one. While this may
sometimes be justified, if we look beyond the common definition of a traditional IBD
“flare” consisting of a full-blown adaptive immune response, we should consider the
possibility that the intermittent symptoms may be occurring due to less catastrophic
changes occurring in the intestinal epithelial cells. Evidence for this concept can be
found, to a small extent, in the analysis of tight junction proteins from tissue taken from
the distal colon of mice from the DSS colitis experiment. By Western blot analysis of
those proteins, it appears that EGCG significantly alters the constituent components of
the tight junctions in a manner that has important ramifications for ion and water
transport across the epithelial barrier. The main clinical impact of changing ion transport
across the intestinal epithelium into the lumen would be to alter diarrheal symptoms.
Diarrhea is one of the most prominent symptoms in both ulcerative colitis and Crohn’s
disease. Current anti-diarrheal therapies do not target the source of diarrhea (ion flux and
subsequent water movement into the lumen), they only mask the symptoms by slowing
motility through their effects on intestinal opioid receptors (Holzer 2014). Indeed, antidiarrheal therapies often result in uncomfortable constipation and can occasionally induce
more serious complications such as toxic megacolon (Strong 2010). A more holistic
approach would involve the administration of substances that actually manage immune
responses of the intestinal barrier and address the root cause of the diarrhea problem: that
is, manage the rapidly inducible fluctuations in tight junction proteins that cause shortterm changes in ion and water movement across a “semi”-permeable barrier while
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suppressing inflammation from contact with bacterial antigens. Based on the findings
from our evaluation of the DSS model of colitis, we next turned our attention to how
EGCG affected the barrier function of the intestinal epithelium by performing a number
of illuminating experiments using intestinal epithelial cell lines.
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CHAPTER 5
EFFECT OF EGCG ON TIGHT JUNCTION COMPOSITION AND FUNCTION

5.1 INTRODUCTION
Certain clinical data suggest that a primary barrier defect may be present in IBD
patients and their first-degree relatives (Hollander, Vadheim et al. 1986), while other
reports conclude differently (Teahon, Smethurst et al. 1992, Munkholm, Langholz et al.
1994). In either event, the origin of that potential barrier defect or the actual barrier
problems observed in active IBD remains imprecisely defined. The inciting event could
be caused by a primary barrier etiology (such as those seen in pathogenic infections or
non-steroidal anti-inflammatory induced injury), or it could be due to low-grade
inflammation from infiltrating immune cells. When it comes to evaluating the status of
TJ protein contribution to IBD pathophysiology, the story becomes even more confusing.
Insight into the various roles that tight junctions play in intestinal barrier function
continues to evolve. Two methods exist for transporting material across the epithelial
barrier:

either around or through the cells making up the border of the intestine

(Anderson and Van Itallie 2009).

The intestinal border consists of a variety of

specialized cells, but the vast majority of the surface is covered by enterocytes bound
tightly together by a multitude of interwoven strands of TJ proteins (Schneeberger and
Lynch 2004). Originally felt to be inert solute barriers, our understanding now points to
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the fact that the TJ composition is controlled by a highly complex regulatory system that
causes rapid changes in TJ elements based on environmental conditions. IECs take cues
from both the basolateral interface with the luminal environment, as well as, the apical
interface with the lamina propria.

As the largest absorptive surface area of the body, the chief role of the intestinal
epithelium involves moving nutrients across the barrier from the lumen to the inner layer.
This process is most important in the proximal gut, which also carries the lowest burden
of intestinal bacteria. Here, the absorptive process often relies on carrier proteins for bulk
movement of specific nutrients (Rao, Sarathy et al. 2015). The lower digestive tract
carries out relatively little absorption compared to the upper tract, but must cope with the
largest exposure to commensal bacteria. Two separate pathways exist for the transport of
materials across the epithelial barrier. The first consisting of a charge selective system of
pores up to 4 Å in diameter, the second involving larger discontinuities in the membrane
that are indifferent to charge status (Anderson and Van Itallie 2009). Paracellular ion
movement is determined by the claudin composition of the epithelial cells, which varies
over the length of the digestive tract (Anderson and Van Itallie 2009). Transcellular
transport generally requires carrier proteins, although specialized epithelial cells such as
M cells, permit wholesale transport of large antigen particles via tunnels that facilitate
transcellular extension of dendrites from follicular-associated epithelial dendritic cells
(Lelouard, Fallet et al.). The relative movement of ions across an epithelial barrier
depends on the resistance of the barrier, as diagramed in figure 19. Changes in barrier
permeability are dictated by resistors (which represent claudins in the actual barrier).
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Figure 19. Model of Transepithelial Resistance.
Representation of the epithelial barrier function
modeled after an electrical circuit. Author unknown.
Several cell lines exist for investigating how TJ respond to various stimuli, such as
cytokines or bacterial/food antigens. One of the most frequently studied is the Caco-2
cell line. Given the fact that the Caco-2 cell line is derived from a human colon cancer, it
is not surprising to learn that the electrical resistance resembles that of the distal colon
(Van Itallie and Anderson).

This resistive property provides a firm foundation for

developing a robust model for evaluating the effects of therapeutics on the TJ’s
contribution to intestinal physiology.

The relative contribution of individual claudins to barrier resistance (and
permeability, to a certain extent) has been established by knocking out or establishing a
constitutively active form of the various claudin genes. For instance, the importance of
claudin 1 as a contributor to maintaining barrier integrity can be inferred based on a
hypothesis developed by Furuse after observing that claudin 1 deficient mice die of
dehydration after birth (Furuse, Hata et al. 2002) and confirmed when experiments
overexpressing claudin 1 led to increased TER (Inai, Kobayashi J Fau - Shibata et al. ,
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McCarthy, Francis et al. 2000). Furthermore, expression of claudin 2 in cultured cell
lines selectively alters permeability for solutes smaller than 4 Å, while the pores formed
by claudins 4 and 18 pores allow for passage of larger molecules without sensitivity for
charge (Van Itallie, Holmes et al. 2008). These contrasting discriminant features create
incongruencies when interpreting results, as similar pores in different membrane settings
may discriminate differently on similar electrical charges, or monomeric expression of
certain “tightening” claudin blocks ion passage based on charge selectivity, while coexpression of that same claudin with a different claudin leads to diametrically opposite
permeability to solutes (causing a diarrheal state in the intestine) while the ion
permeability remains low (still possesses a high TER).

The juxtaposition of size versus charge may be readily sorted out in the lab, where
precise manipulation of cell lines allows for accurate measurement of physiologic
outcomes, but physical realities can promote confusion in the clinical setting when
interpreting the role of TJ proteins in health or inflammatory bowel disease. For instance,
some investigators found evidence for the upregulation of claudin 1 (a pore sealing
claudin) in some patients with IBD, while others showed no change or even downregulation in their patients with IBD (Kucharzik, Walsh et al. 2001, Zeissig, Bürgel et al.
2007, Weber, Nalle et al. 2008). On the other hand, claudin 2 is regularly associated with
paracellular leakiness and has frequently been found to be upregulated in clinically active
Crohn’s disease but not in normal controls (Zeissig, Bürgel et al. 2007). However,
claudins 3 and 8 have shown variably decreases in Crohn’s disease compared to controls,
while claudin 4 did not change (Zeissig, Bürgel et al. 2007). Others have confirmed
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elevated expression of claudin 2 in inflamed colonic epithelium, but diminished levels or
topographical redistribution of claudin 4 (Prasad, Mingrino et al. 2005). One reason for
the confusion lies in the fact that a consistency in baseline conditions can be difficult to
establish. Due to the risk, cost and inconvenience of endoscopy in humans, the basis for
the permeability changes shared between IBD patients and their first degree relatives
mentioned previously (Hollander, Vadheim et al. 1986)has never been identified.
Second, the claudin composition of normal intestine versus inflamed intestine differs
within the same individual, depending on the proximity of the biopsy to the inflamed
mucosa, relative location in the bowel, or even chronological stage of the disease, making
precise determinations difficult and generalizations more common. Third, the alterations
in claudin composition may vary depending on the etiology of the inflammation (Heller,
Florian et al. 2005, Prasad, Mingrino et al. 2005).

Little is known regarding the effects of EGCG on claudin physiology. EGCG has
been shown to not change claudin 1 expression in a liver cell line (Ciesek, von Hahn et
al. 2011), while it reduced inflammatory cytokine-based changes to claudin 5 and
occludin in cultured vascular endothelial cells (Li, Ye et al. 2012). Based on the fact that
EGCG is readily taken up by IECs when administered orally, and that it has been shown
to reduce secretion of inflammatory cytokines associated with barrier disruption, we
sought to evaluate the effects of EGCG on epithelial integrity and key tight junctions
associated with the pathophysiology of IBD.

5.2 RESULTS
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5.2.1 EFFECT OF EGCG ON EPITHELIAL BARRIER FUNCTION AFTER LPS
CHALLENGE
In order to determine whether EGCG could effectively restore TJ composition
after LPS exposure, Caco2 cells were co-cultured with two concentrations of EGCG, both
in the presence or absence of LPS exposure. TJ composition plays a role in maintaining
epithelial barrier function. As TJ relax or open in response to changes in TJ claudin
composition, electrical resistance goes down due to increased ion flux across the
epithelial barrier. After TJ homeostasis is restored, electrical resistance rises.
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Figure 20. Effect of LPS and EGCG on Caco2 model of epithelial
barrier. Caco2 cells were cultured for TER testing with two doses
of EGCG). Data are expressed as a ratio of TER experimental
condition to TER control values for each time point. The results
shown are representative of data obtained from three independent
experiments. **P<0.01; *P<0.05.
Figure 20 demonstrates that trans-epithelial resistance dropped significantly from
baseline within 12 hours of exposure to LPS, with no evidence of improvement by 24
hours. However, the reduction in TER was abrogated by the addition of EGCG. The
highest dose of EGCG (10 µg/ml) provided the most robust protection against LPS-
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induced degradation of TER, returning levels to near baseline within 18-24 hours after
exposing Caco2 cell monolayers to LPS and EGCG. Interestingly, the presence of
EGCG in culture medium in cells not exposed to LPS actually caused a rise in TER
above the baseline of control Caco2 cells.
5.2.3 EFFECT OF EGCG ON TJ PROTEIN PRODUCTION AT BASELINE AND
AFTER STIMULATION WITH LPS
Based on the dramatic changes in TER that were seen in Figure 20, an
understanding of the relative composition of TJ proteins expressed in those cells was
sought. In order to accomplish this task, semi-quantitative analysis of the individual TJ
of interest was performed by Western blot analysis.
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(C) RT-PCR for selected claudins.

Caco2 cultures exhibited significant differences in the relative production of specific TJ
proteins after LPS exposure (figure 21). The most significant change was noted with
claudin 2, a claudin found to be upregulated during acute colitis (Lu, Ding et al. 2013).
Claudin 2 protein levels increased in our model by more than 200% after exposure to
LPS. Co-incubation with EGCG 5 µg/ml actually reduced claudin 2 levels by 25% below
the basal production of un-stimulated cells. Claudin 4, a pore-tightening TJ protein
associated with inflammation did not appear to be affected by LPS on a protein level, but
message expression increased 130 fold by RT-PCR. Upon exposure to EGCG, claudin 4
message was completely suppressed and could not be rescued by post-exposure to LPS
after an initial exposure to EGCG, and protein levels fell to 35% of basal production
when cells were incubated with both LPS and EGCG. Levels of claudin 1, a pore
tightening claudin, dropped by over 60% from basal levels in response to LPS exposure,
but returned to baseline upon adding EGCG to culture medium. By RT-PCR, message
for claudin 1 increased by 16-18 fold from EGCG exposure alone, but most intriguing
was what happened after pre-incubating Caco-2 cells with EGCG then LPS. Claudin 1
levels skyrocketed by 508 fold according to RT-PCR.

Finally, occludin, a barrier

enhancing TJ protein, also decreased in response to LPS but was rescued by EGCG. LPS
impacted the TJ protein ZO-1 the least, with approximately a 33% reduction from
baseline protein levels in the control samples.

However, incubation with EGCG

increased ZO-1 protein levels by over 50% from baseline. This variable impact in
subsets of TJ proteins makes sense in light of the unique role each component plays in the
function of a tight junction. ZO-1 forms the foundation for TJ construction, acting as a
scaffold protein upon which the tight junction is built, while the accessory components
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(claudins and occludins) fluctuate in response to the local environmental or physiologic
needs of the barrier function. Although the relative protein levels fluctuate dramatically
in some cases, the importance of these changes to physiological function can only be
measured by functional assays. Combined with data from the TER experiment, it appears
that the “tightening” protein claudin 1 plays a large role in augmenting barrier resistance
after EGCG exposure, while claudin 2, a “leaky” protein, is suppressed by the
administration of EGCG. EGCG’s suppression of claudin 4, according to our Western
blot and RT-PCR data, bring into question its role as a tightening claudin. How can
rising levels of a “tightening” claudin in the setting of an increasingly “leaky” barrier in
response to LPS be interpreted, especially when the “tightening” of that barrier in the
setting of EGCG occurs without a rise in claudin 4? The answer lies in part with the
concept of relative contributions from TJ proteins, as supported by additional
experiments showing changes in relative abundance and claudin distribution. In this set
of experiments, Caco-2 cells were exposed to LPS for 3 hours, washed, then incubated
with or without EGCG at clinically relevant doses of 5 and 10 µg/ml. Cells were then
washed with fresh medium and prepared for analysis, as reported in Chapter 2.

5.2.6 BARRIER PERMEABILITY CHANGES LIKELY RELATED TO RELATIVE
CLAUDIN EXPRESSION AND DISTRIBUTION
The expression of claudin 2 itself, which rose 225 fold after LPS exposure,
sufficiently alters epithelial monolayer porosity to allow net flux of positive sodium ions,
while prohibiting passage of larger molecules such as lactulose or mannitol (Amasheh,
Meiri et al. 2002). Simultaneous with the rise in claudin 2, LPS increased claudin 8
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levels by 6 fold. This change in relative concentration of claudins 4 and 8 change helps
explain how a “tightening” claudin (that is, claudin 4) can become more plentiful while
the barrier resistance drops. Others have shown that when claudin 4 co-expresses with
claudin 8, the combination of claudins forms a pore for negatively charged chloride ions
(Hou, Renigunta et al. 2010). The movement of chloride ions into the lumen promotes
diarrhea, such as that occurring after cholera toxin induced calcium activated (CLCA)
chloride channel cyclic AMP mediated opening of the cystic fibrosis transmembrane
conductance regulator (CFTR) channel, which have been harnessed pharmacologically to
treat chronic idiopathic constipation (Hodges and Gill 2010). The pattern of claudin 4/8
co-expression found in our experiment with Caco-2 cells helps explain the paradoxical
drop in electrical resistance seen after LPS exposure. Furthermore, the dramatic rise in
claudin 4 mRNA transcripts after administration of LPS was fully suppressed by EGCG,
and LPS could not elevate claudin 4 after exposure to either concentration of EGCG.
Claudin 1 protein levels, on the other hand, were initially supressed by LPS, but either
pre- or post-LPS exposure to EGCG enhanced claudin 1 message levels enormously.

On the other hand, LPS appeared to have no effect on claudin 1 expression, while
exposure to EGCG alone increased claudin 1 transcripts significantly in a dose dependent
fashion.

When Caco-2 cells were pretreated with LPS, claudin 1 transcripts were

suppressed relative to EGCG exposure alone, but when cells were pretreated with EGCG
followed by LPS, a synergistic, dose dependent surge of claudin 1 transcripts followed.
This finding is likely explained by effects of EGCG on HIF1a stabilization. Increased
levels of HIF1α appear to be related to HIF1α protein stabilization in response to mir201,
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an important microRNA induced by EGCG. The CLDN1 promoter has been shown to be
a prominent target for HIF1α binding by ChIP-on-chip analysis (Saeedi, Kao et al. 2015),
has been shown to bind to the promoter for claudin 1 with subsequent rises in claudin 1
protein production. In order to gain a better understanding of this relationship, we have
initiated an active line of investigation to determine possible clinical implications.

5.2.6 EGCG IMPARTS A DISPARATE EFFECT ON TJ PROTEINS AS
DEMONSTRATED BY IMMUNOFLUORESCENCE OF HT-29 CELLS
Immunofluorescence can provide additional information about protein function,
especially in situations where the physical location of proteins within the cell provide
meaningful context regarding their physiological role. In the case of claudin proteins,
impact on barrier resistance to ion passage requires insertion of the protein into the cell
membrane, so that the extracellular loops of the protein can interact with claudin loops
from neighboring cells for the creation of ion channels. In order to correlate the data
derived from Western blot and RT-PCR of important pore forming claudins with the
provocative TER data, immunofluorescence imaging of the most conspicuous proteins,
claudins 1 and 4, was undertaken. HT-29 cells were grown under standard conditions
and exposed to LPS with or without EGCG, depending on the parameters dictated by the
arm of the experiment. In order to investigate the concept that EGCG could be used as a
preventative agent on non-inflamed mucosa to prevent effects from bacterial antigens,
cells in one experimental arm were exposed to EGCG prior to LPS, while the response to
a “treatment effect” was examined by pre-conditioning cells with LPS for three hours
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prior to exposing them to EGCG. Supernatants were taken for cytokine analysis and cells
were harvested for mRNA and protein isolation according to standard protocols.

Figure 22. Immunofluorescence of TJ proteins under experimental conditions. HT-29
cells were cultured with or without LPS, and with or without two doses of EGCG.
Immunofluorescence for either claudin 1 or claudin 4 showed striking differences in both
quantity of protein expression as well as location of protein.
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Although technological considerations make quantification of fluorescence
difficult and subsequent comparisons between conditions inaccurate, gross differences in
appearance of the relative fluorescence intensity based on experimental conditions
provide insight into the functional status of claudins 1 and 4 (figure 22). EGCG clearly
has an antithetical effect on claudin production and distribution within the cellular
architecture. In the presence of LPS, claudin 1 expression did not change, but in the
presence of EGCG, claudin 1 expression increased and the resulting protein was
distributed to the inner aspect of the cell membrane, where it can materially participate in
sealing the gap between cells. On the other hand, claudin 4 mRNA and protein levels
noticeably rose in response to LPS. Interestingly, claudin 4 staining revealed an even
distribution of protein throughout the cytoplasm. The addition of EGCG by itself had no
effect on claudin 4 message or protein, but the administration of EGCG after LPS
appeared to not only diminish the amount of claudin 4 protein, but it also appeared to
cause the claudin 4 to redistribute and concentrate around the nucleus. The functional
ramifications of this rearrangement are not clear, but it speaks to the fact that claudin 4
can no longer participating in a sealing capacity at the cell membrane.
5.2.7 EGCG EFFECTS EXPRESSION OF BOTH Muc1 and Muc2 GENES IN THE
DSS COLITIS MODEL
Mucins are ubiquitous proteins produced mainly by goblet cells contained in the
epithelial layers lining the internal interfaces between the body and the environment. The
most abundant mucin proteins produced in the gastrointestinal tract are encoded by
MUC1 and MUC2. The protein products of these genes differ in structure and function.
The protein encoded by MUC1 contains a transmembrane component that localizes the
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protein to the apical membrane of the IEC, and may be involved in cell signaling,
detection of cell-cell contact, or docking of signaling proteins for intracellular
communication (Kim and Ho 2010).

Mice deficient in Muc1 have increased

susceptibility to certain infections and increased susceptibility to autoimmune disorders
such as EAE (Kim and Ho 2010). Along those lines, MUC1 mucin has also been shown
to negatively regulate the NLRP3 inflammasome through reduced interleukin-1 receptorassociated kinase (IRAK4)-dependent NF-κB activation, with the resulting suppression
of inflammation providing a protective mechanism against lethality from Helicobacter
pylori infection (Ng, Menheniott et al. 2015). On the other hand, the protein encoded by
MUC2 is a gel-forming protein that constitutes the bulk of the intestinal mucin layer that
creates the physical barrier between the IECs and the microbiome (Kim and Ho 2010).
MUC2 mucin polymerizes to form a dense hydrogel that separates into two layers as seen
in figure 23: a thinner, firmly adherent sterile layer adjacent to the IECs and a much
thicker, loosely connected layer that acts as a trap for secreted antimicrobial peptides,
antibodies and bacterial products (Kim and Ho 2010).
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Figure 23. Mucin content of epithelial border. (A) left Graphic of mucin layers on
top of the epithelial barrier, consisting of a mucosally adherent layer of mucin 1,
topped off by two densities of mucin 2 material. From: (Kim and Ho 2010). (B) right
The relative production (by RT-PCR) of mucins differed by EGCG treatment group.

We saw no changes in Muc1 expression with LPS exposure in Caco2 or HT-29
cell lines (data not shown), but we wanted to determine whether chronic administration of
EGCG in the DSS model of colitis altered mucin gene expression over time. Although
increased mucin levels from elevated Muc1 expression have been implicated in causing
increased Th17 activity, instead of exacerbating epithelial injury, the downstream effect
of enhanced mucin production ultimately acts to promote barrier restitution through the
intensification of the restorative effects of IL-22 (Nishida, Lau et al. 2012). On the other
hand, the intestinal epithelial cells of mice deficient in Muc2 undergo excessive exposure
to antigens from both gram positive and gram negative bacteria leading to the
development of massive inflammation and eventually colon cancer (Dohrman, Miyata et
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al. 1998). In the setting of Muc2 deficiency, bacteria directly interface with the epithelial
surface of the intestine of Muc2-/- animals (Johansson, Phillipson et al. 2008).
Upregulation of Muc2 gene expression occurs diametrically in response to LPS, a TLR-4
agonist, as opposed to MDP, a TLR-2 agonist (Rodrigues, Slobbe et al. 2015). Indeed,
mice treated with DSS alone demonstrated a massive upregulation of Muc2, and to a
lesser extent, Muc1 (figure 23), which was blocked in animals treated with early EGCG
(prior to the onset of inflammation). Instead of the robust DSS-triggered TLR stimulation
driving increases in Muc2 expression, we actually detected an initial fall in both Muc1
and Muc2 readouts. Animals treated with late EGCG had attenuated levels mRNA
production, suggesting a suppressive effect that occurred after LPS initiated an
upregulation of Muc2 expression. This finding is plausible, given the fact that EGCG
inhibits signaling pathways emanating from activation of both TLR-2 and TLR-4 (which
is activated by LPS) (Lee, Yeo et al. 2004, Hirao, Yumoto et al. 2010). Others have
shown that over time, DSS decreases Muc2 expression by 15-18 fold around days 3-6,
which is accompanied by goblet cell depletion (Dharmani, Leung et al. 2011). The loss
of goblet cells and disappearing mucin layer heralds the onset of inflammatory immune
cell infiltrates and deteriorating clinical conditions. However, in our experience, while
the massive upregulation of Muc2 mRNA seen in animals treated with DSS was
suppressed with EGCG, relative expression of Muc1 increased in a dose dependent
fashion to EGCG. In our experience, this correlated with a well maintained goblet cell
population in animals treated with EGCG compared to controls. In the context of a
reactive treatment paradigm, the DSS-dependent expression of Muc2 was strongly downregulated by EGCG, causing a 3-fold reduction in mRNA expression in the EGCG
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treated animals, while preventative treatment almost completely subdues Muc2
transcripts to water-fed baseline levels. The reduction of Muc2 gene expression tracks
with a lower endoscopic score in animals treated pre-emptively with EGCG, and more
rapid endoscopic recovery after administration of EGCG in a treatment protocol (see data
in chapter 5). Gene expression of Muc1, however, increased with longer periods of
exposure to EGCG, and higher levels inversely corresponded lower inflammatory
measures. In line with this finding, Muc1 appears to extend a protective effect to DSS
treated animals by converting Th17 inflammatory signals from pathogenic T cells into a
healing effect by enhancing mucosal responses to IL-22 (Nishida, Lau et al. 2012). The
comprehensive benefits from orally administered EGCG in DSS exposed mice
demonstrated a parallel dose-dependent response, as greater protective effects from
colitis were seen with the higher dose of EGCG (20µg/ml) than with the lower dose
(EGCG 2µg/ml).

5.2.8

MMP9, A MAJOR DETERMINANT OF COLITIS, IS STRONGLY

DOWNREGULATED BY EGCG ADMINSTRATION
Matrix metalloproteinase (MMP)-9 has demonstrated a role in initiating and
determining the severity of colitis in both animal models of inflammation and human
IBD (Medina, Santana et al. 2006, Garg, Vijay-Kumar et al. 2009, Annaházi, Molnár et
al. 2012). Mice with deleted or inhibited MMP-9 are protected against colitis, and
treatments directed at inhibiting MMP-9 effects on extracellular matrix can improve
colitis (Shimshoni, Yablecovitch et al. 2015) .
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Figure 24. MMP9 transcripts.
MMP9 mRNA message level
was evaluated by RT-PCR for 3
treatment conditions.

tissue from DSS only treated animals exhibited a
dramatic rise in MMP9 transcripts, while both
treatment regimens profoundly inhibited the DSSinduced stimulatory effects on MMP9. It appears

that early administration of EGCG completely prevents the induction of MMP9 mRNA
production. From a treatment consideration, even when waiting for the inflammation to
become established, EGCG still retains the ability to suppress MMP9 mRNA
transcription to a fraction of the untreated animals. To put these findings into context,
elevated MMP9 mRNA and protein levels in infiltrating immune cells correlate directly
with severity of colitis (Medina and Radomski 2006, Medina, Santana et al. 2006,
Santana, Medina et al. 2006). Elevated stool levels of MMP9 in humans with IBD
correlate with disease activity (Annaházi, Molnár et al. 2012), and this protein is now the
active target of pharmaceutical manipulation by monoclonal antibody therapy for treating
the human disease state (Adamkewicz, Smith et al. 2013).

5.3 DISCUSSION
Barrier function may be one of the most important, yet under appreciated,
components of the IBD susceptibility triad. Barrier disruption by medications such as
nonsteroidal anti-inflammatory drugs, pathogenic bacteria, or even shifts in the
microbiome can induce the onset of IBD. First degree relatives of IBD patients, who
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have increased barrier permeability (Hollander, Vadheim et al. 1986), also have higher
rates of developing IBD as well (Kevans, Silverberg et al. , Gaya, Russell et al. 2006,
Van Limbergen, Russell et al. 2007). One IBD susceptibility mutation in particular,
encoded by the XBP1 mutation (Kaser, Flak et al. 2011), directly impacts autophagyrelated epithelial homeostasis and points to a genetic factor that could tie abnormal
barrier permeability to first degree relatives of IBD patients (Fowler, Doecke et al. 2008).

One persisting unanswered chicken and egg question remains: that is, which
problem comes first? Does the barrier defect exist first, then leads to an abnormal
immune response, or does the activation of intestinal inflammation leave intestinal
permeability in a shambles as an unintended consequence of the inflammatory cytokine
storm? The answer could have relevance to future work developing IBD therapies. With
our ever expanding knowledge of the intricacies of the mechanisms of inflammation
guiding drug development, new therapies generally target the newest pathway
discovered. Drug targets with broad effects on the immune system, such as TNF-α, have
provided significantly better relief than non-specific immunomodulators such as
azathioprine, 6-mercaptopurine or methotrexate.

However, targeting other pervasive

cytokines such as IL-6 or IL-1β have not provided relief, while drugs targeting very
specific downstream cytokines, such as antibodies directed against IL-17, have actually
worsened inflammation in treated patients compared to controls (Hueber, Sands et al.
2012). In retrospect, it turns out that interrupting IL-17 effects prevented compensatory
increases in IL-22, which resulted in a cascading worsening of barrier function followed
by heightened inflammation (Eyerich, Eyerich et al. 2010). Clinical trials, by design,
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generally implement one primary intervention, though multiple outcomes may be
measured. As clinical trial acumen improves, our so does our ability to interpret the
results. We have now to come to a consensus in IBD trials that clinical do not provide
reliable results for evaluating the success of a treatment. Therefore, newer clinical trials
have started targeting mucosal healing as the primary or co-primary outcome to measure
success of the trial for both Crohn’s disease (ClinicalTrials.gov identifier NCT02596893)
and ulcerative colitis (Dave and Loftus 2012). However, the recognition of mucosal
healing as a worthwhile outcome has not yet translated into a focus for drug
development. Based on our observations, agents that provide both a healing stimulus as
well as an anti-inflammatory effect on the intestinal epithelial barrier provide a
synergistic effect that translate into excellent outcomes. By the work detailed in this
chapter, we have laid a substantial foundation for using EGCG as a therapeutic agent in
IBD patients, especially for ulcerative colitis. First, EGCG exerts a beneficial effect on
the composition of tight junction proteins in the colonic epithelium of mice treated with
DSS and on human epithelial cells treated with LPS by promoting the production of tight
junction “tightening” claudins while decreasing “loosening” claudins. Further support
comes from measurements of Caco2 monolayer resistance to the passage of current
(TER), showing that EGCG attenuates the loss of resistance induced by administrating
LPS. In the absence of LPS, the administration of EGCG elevates TER above that of
control Caco-2 cells, suggesting that cells do not require an inflammatory stimulus to
respond to the effects of EGCG. This provides us a great deal of confidence as we plan
clinical trials to evaluate the effects of EGCG on post-operative Crohn’s disease patients.
We feel that EGCG will prevent the return of inflammation that normally occurs in 70-
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90% within one year of intestinal resection by bolstering epithelial resistance to antigen
penetration, reduce diarrheal symptoms by augmenting expression of “tightening”
claudins, and impart an anti-inflammatory effect on intestinal epithelial cells, circulating
immune cells, and especially lamina propria immune cells. Other potential benefits from
EGCG stem from its ability to reduce MMP9 production (an early manifestation of and
possible precipitator of inflammation) and improve the quality of the mucin layer by
enhancing mucin 1 production to assist with mucosal healing through effects of lamina
propria produced IL-22 (Nishida, Lau et al. 2012). These data, plus additional data
described previously, provide a sound basis for the evaluation of EGCG in further clinical
trials for IBD.
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CHAPTER 6

CLINICAL EFFECT OF EGCG ON HUMAN UCLERATIVE COLITIS1

6.1 INTRODUCTION
The treatment of patients with active UC generally follows a step-wise approach,
beginning with the administration of 5-aminosalicylic acid (ASA) agents.

While a

majority of UC patients respond to topically active 5-aminosalicyclic acid (5-ASA)
preparations currently available, up to 35% of patients fail to respond initially and 20% of
responders lose efficacy over time (Howell 2008). Refractory cases of UC require an
escalation in therapy, usually involving steroids, immunomodulators, biologic agents, or
various combinations of all three to attain remission. The fact that multiple forms of
susceptibility (genetic, immunologic) culminate in one common clinical manifestation
that is recognized as ulcerative colitis, likely explains why no single therapy works for all
affected individuals. Although all 5-ASA agents are considered quite safe, the therapies
used during escalation for those with partial or no response to 5-ASA exhibit a relatively

The results discussed in this chapter have been published in Inflammatory Bowel
Diseases, Volume 19, No. 9, pp 1904-1992 (2013) titled “A pilot study to evaluate the
safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich Polyphenon E in
patients with mild to moderate ulcerative colitis”.
Authors: Dryden G, Lam A, Beatty K, Qazzaz H, and McClain C.
1
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high propensity for inducing significant side effects. For this reason and others, a large
number of patients have turned to complementary and alternative medicine (CAM), either
as an adjunctive therapy (complementary) to their current regimen or as a substitute for
conventional therapy (alternative) (Hilsden, Scott et al. 1998, Ganguli, Cawdron et al.
2004).

6.1.1 ROLE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN IBD
Patients managing chronic disease states, such as diabetes or hypertension (which
are generally well controlled with conventional therapy) are less likely to use CAM than
patients with disease processes that exhibit a variable response to commercially available
medications (Eisenberg, Davis et al. 1988).

In light of this fact, patients with

gastrointestinal diseases (particularly inflammatory bowel diseases) find dissatisfaction
with conventional medicine (Hilsden, Scott et al. 1998). Several CAM agents under
investigation for IBD have demonstrated an ability to modulate inflammation, alter gut
flora, or reduce psychosocial stress (Krueger, Wright et al. 2004, McClain, Dryden et al.
2008). Unfortunately, clinical evidence for the therapeutic claims of CAM agents is
often limited, and safety issues have often been inadequately addressed.

6.2 CLINICAL TRIAL CONSIDERATIONS:

SUBJECT DEMOGRAPHICS,

RANDOMIZATION SCHEME, AND DISPOSITION
A total of 30 patients were screened for inclusion. Twenty patients met all
inclusion and exclusion criteria and were enrolled in the study. The demographics of
each group are summarized in Table 5. There were no statistically significant differences
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between treatment groups according to height, weight, UCDAI or baseline laboratory
values such as white blood cell count (WBC), hemoglobin (Hgb), hematocrit (Hct), AST,
ALT, and c-reactive protein (CRP) (Table 5). However, subjects randomized to the
placebo arm did have a significantly lower baseline IBDQ score (Table 5).

All

randomized subjects were taking 5-ASA medications at time of enrollment. Almost half
(7 of 16) of subjects randomized to active therapy were also taking AZA/6-MP. No
subjects randomized to placebo were taking an immunomodulator at enrollment. Four
subjects had previously received steroid therapy.
Age
Weight
Male gender
Tobacco use
Azathioprine use
Day 0 DAI
Day 0 IBDQ
Day 0 Endo score
Day 0 CRP

Polyphenon E

Placebo

p value

44.9 +/- 15
84.8 +/- 14.2 (61-77)
46.7
7%
5
6.5 +/- 1.9 (4-10)
152.3 +/- 26 (108-206)
2 +/- 0.68 (1-3)
0.702 +/- 0.89 (0.03-2.8)

30.7 +/- 14.4
76.7 +/-8.1 (70-88)
0%
50%
0
7.3 +/- 1.7 (5-9)
101.3 +/- 21.4 (77-129)
2 +/- 0.5 (1-2)
1.5 +/- 2.1 (0.13-3.9)

p=0.26
p=0.29
p=0.5
p=0.11
p=0.64
p =0.5
p = 0.02
p>0.99
p=0.27

Table 5. Baseline characteristics for randomized subjects. Both the low-dose and highdose cohorts were combined for analysis. No statistically significant differences were
noted in any category, with the exception of IBDQ score in the placebo group. A lower
IBDQ score suggests more severe disease. The treatment group contained all of the
patients refractory to azathioprine.
A total of sixteen subjects were randomized to receive study drug (low vs. high
dose Polyphenon E®), while four subjects were randomized to receive placebo. One
subject assigned to treatment with Polyphenon E®, who withdrew just after
randomization but before receiving any therapy, was excluded from final analysis. Three
subjects assigned to active therapy voluntarily withdrew during the study period due to
lack of efficacy (two in the low-dose cohort, one in the high-dose cohort). One subject
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randomized to placebo withdrew prior to completion of the study. All drop-out subjects
were coded as non-responders. (See Figure 25 for Subject Allocation).
30 Subjects screened
20 Subjects
randomized
4:1 randomization
treatment to
placebo

Cohort 1:
10 subjects
Low dose EGCG
-5 completed
-3 withdrew*

Placebo
-1 completed
-1 withdrew

Cohort 2:
10 subjects

High dose EGCG
-8 completed

Placebo
-2 completed

*One withdrew prior to dosing with EGCG.
Figure 25. Subject allocation. Subjects were assigned to treatment at random.
6.3 RESULTS

6.3.1 EFFECT OF EGCG ON OVERALL TREATMENT OUTCOMES OF CLINICAL
RESPONSE
Subjects were evaluated for response after 56 days of therapy by UCDAI. As
demonstrated in Figure 26, a total of 10 of 15 (66.7%) subjects randomized to
Polyphenon E® (aggregates of cohorts I and II) responded to therapy, as evidenced by a
decrease in their UCDAI score by at least three points (p = 0.03), (OR 17.2, 95% CI 0.77381.1). When response rates were evaluated by individual treatment group (low or high
dose Polyphenon E® or placebo), overall response rates for the active therapies appeared
similar irrespective of dose (Figure 27). Both high and low dose groups contained a
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majority of responders. No formal comparisons were made for the individual treatment
groups, due to the small number of subjects in each group.

6.3.2 EFFECT OF EGCG ON OVERALL TREATMENT OUTCOMES OF CLINICAL
REMISSION
Eight of 15 (53.3%) subjects (p=0.07), (OR 10.2, 95% CI 0.47-222.6) who
received active therapy went into remission, as evidenced by a UCDAI < 2. Some
subjects qualified as both responders and remitters, depending on their UCDAI score on
day 0. No subjects randomized to placebo demonstrated either a response or remission to
study medication. When evaluated separately, both active therapy dosing regimens of
Polyphenon E® appeared to have similar patterns of response (Figure 27).

Figure 26. Combined response and remission rates. Subjects treated
with EGCG had a statistically significant response to therapy.
6.3.2.1 ANALYSIS OF INDIVIDUAL RESPONSES BASED ON TREATMENT
ASSIGNMENT
The following graphs represent the individual treatment responses, based on
either high dose EGCG, low dose EGCG, or placebo. The only patient exhibiting a
worsening of symptoms during the clinical trial actually developed infection with C.
difficile after a course of antibiotics for an unrelated infection.
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Figure 27. Individual responses to EGCG based on dose of EGCG or placebo.
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Figure 28. Impact on QoL by different doses of EGCG or placebo. A rising IBDQ
indicates improving quality of life. A majority of subjects treated with EGCG
experienced a rise in their IBD, while most randomized to placebo did not.
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6.3.4 IMPACT OF EGCG ON MUCOSAL INFLAMMATION AS DETERMINED BY
SERIAL ENDOSCOPY
All subjects underwent flexible sigmoidoscopy on day 0. All but one subject
completing the full treatment course underwent a follow up procedure. Only one subject
randomized to active therapy demonstrated a worsening in the endoscopic score after
therapy. All subjects who clinically responded to treatment with Polyphenon E® (10/15)
also exhibited at least a single point drop in the endoscopic score. Two subjects receiving
active therapy demonstrated a dramatic 3-point drop in their endoscopic score, and their
images are highlighted in Figure 4. A total of 5 subjects completed the study with an
endoscopic score of 0. There were no clinical non-responders who received active
therapy who also exhibited a drop in their endoscopic score. Only one subject
randomized to placebo demonstrated an improvement in the endoscopic component of
the UCDAI, changing from a score of 2 to 1 at day 56.

Figure 29. Endoscopic response to orally administered EGCG. Figure 29 demonstrates
clinical effect of EGCG administered over a 56-day clinical trial. The initial picture
depicts a grade 3 colitis as evidenced by the presence of spontaneous hemorrhage and
diffuse erythema, edema and granularity of the mucosa. A follow up picture from the
same patient on day 56 demonstrates complete endoscopic remission occurred due to
the administration of EGCG. The bottom row depicts the effects of continuous
treatment over a 7-year period in a responder from the original clinical trial.
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Figure 30. Seven year followup. (A) demonstrates the white light appearance of a
normal colon. (B) depicts the appearance of the mucosa imaged by narrow band
imaging (NBI), a technique that highlights red to visualize highly vascular
structures. In this picture, NBI shows that the entire rectal mucosa is normal.
This patient had been failed 5-ASA, azathioprine and prednisone. He has
remained in remission, taking EGCG alone.
6.3.5 SUBJECT SAFETY
There were no serious adverse events or greater than grade 2 toxicities related to
treatment. One subject randomized to treatment required hospitalization due to disease
progression, which appeared to be related to antibiotics administered for a non-UC
indication and subsequent Clostridium difficile infection. No significant differences were
noted between pre- and post-treatment laboratory studies, including ALT and AST levels.
The following table summarized the most common study related adverse events.
Symptom
Heartburn
Bloating, flatulence
Nausea
Headache
Increased thirst
Increased diarrhea

Polyphenon E
27%
27%
20%
13%
7%
7%

Placebo
0%
33%
33%
33%
0%
0%

Table 6. Common adverse events. The common adverse events attributed as possible or
likely related to therapy with Polyphenon E® have been listed above. There were no
adverse events exceeding grade 2 severity, according to Common Terminology Criteria
for Adverse Events version 3.0. The small number of subjects enrolled in the placebo
group prevents any meaningful comparison between groups.
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6.4 DISCUSSION
This first ever study of Polyphenon E® in patients with ulcerative colitis provides
convincing preliminary evidence for a significant treatment effect in patients with
inflammatory bowel disease. The observed clinical effect, coupled with a paucity of
acute side-effects, lends strong support for more thorough evaluation of Polyphenon E®
as a therapeutic agent for UC. The numbers of patients enrolled in this study were small,
but with the 4:1 randomization scheme, a large number of subjects were exposed to the
active therapy.

There were two main reasons for randomizing a larger number of

subjects to Polyphenon E® than placebo. First, we wanted to enhance the statistical
confidence regarding response rates in the active therapy group for planning subsequent
clinical trials. Secondly, with a previously untried therapy, we felt that recruitment
would be enhanced if potential subjects felt that they had a better chance of receiving
therapy.

In later phase clinical trials, the risk of randomization to placebo is

counterbalanced by the possibility of rolling over into an open-label arm, but regulatory
constraints prevented this option for our early phase trial. During the final analysis, we
noted that subjects randomized to placebo had a significantly lower IBDQ score, which
could indicate a more severe state in this group.

However, the UCDAI did not

significantly differ between the active and placebo groups.

Considering our positive results from this pioneering clinical trial of Polyphenon
E® in UC, a lack of significant side effects from the therapy, and the mass of pre-clinical
evidence of anti-inflammatory effects of EGCG, we are currently in the process of
planning a subsequent clinical trial to validate the current results. If the improvements
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seen in both clinical and QoL parameters hold up in this difficult to treat demographic (5ASA and/or azathioprine refractory) and Polyphenon E® retains its favorable side-effect
profile, this treatment option would be well placed to serve as an alternate therapy for
first-line therapy of UC, or as an alternative therapy for 5-ASA intolerant patients. The
possibility that Polyphenon E® could also serve as a “step-up” treatment for those
patients who do not respond to either 5-ASA or immunomodulators needs to be further
investigated.

Given the serious side-effect profile of the immunomodulator agents,

Polyphenon E® could potentially become a preferred alternative to this class of
medications.

In summary, we anticipate that the synergy created by a favorable side effect
profile, a commendable efficacy rate against a formidable treatment challenge, and a
convenient once daily dosing schedule will cement the appeal of Polyphenon E® as a
treatment for UC. Taking these results into account, we are planning a continuation of
this line of research in the form of an adequately powered, controlled trial to definitively
confirm the benefits of Polyphenon E® in active UC.
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CHAPTER 7
CONCLUSION: EGCG IS AN EFFECTIVE ANTI-INFLAMMATORY TREATMENT
FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE
While the underlying etiology of IBD remains a mystery, the discovery of new
immunological mechanisms provides a basis for new therapies. Ample evidence supports
a role for the activation and nuclear translocation of NF-κB in the development and
maintenance of IBD (Abboud, Hake et al. 2008). Although an exact mechanism of action
for EGCG has not been established in IBD, the results of our work detailed in this
dissertation point to a multitude of potential roles for EGCG. EGCG exerts a strong
inhibitory effect on NF-κB nuclear translocation through inactivation of IκB kinase
(IKK), which subsequently liberates NF-κB from its inactive cytosolic sequestration by
IκB (Yang, Oz et al. 2001).

Liberated NF-κB traverses the nuclear envelope, and

engages with the promoters of multiple genes, promoting or suppressing gene
transcription. Nuclear translocation of NF-κB within cells of the innate immune system
(such as macrophages and dendritic cells) results in a coordinated increase in the
expression of genes whose products mediate inflammation and immune responses,
including cytokines (e.g., IL-1, IL-6, IL-12, TNF-α), chemokines (e.g., IL-8), enzymes
involved in metabolism (e.g., inducible nitric oxide synthase, inducible cyclooxygenase2), and cell adhesion molecules (e.g., E-selectin, intracellular adhesion molecule-1, and
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vascular adhesion molecule-1). Protein products of these genes are expressed at high
levels in patients with chronic inflammatory bowel disease.

During the process of

disentangling the effects of EGCG on nuclear signaling, it has become evident that
EGCG exerts a much more profound effect on immune regulation of inflammation and
activation of immune cells than can be explained by NF-κB inhibition alone (Wu, Wang
et al. 2012). Insight into the interplay of EGCG with cell signaling events in cancer cells
has greatly expanded our knowledge of the mechanisms of action of EGCG in
inflammation (Khan, Afaq et al. 2006).

EGCG exerts potent inhibitory effects on

signaling intermediaries involved in both generation of inflammation as well as control of
cell growth and proliferation, such as MAPKs, JAKs, and AP-1. A thorough synopsis of
the numerous interactions has been published by Singh et al. (Singh, Akhtar et al. 2010).
We have also demonstrated an effect on RORγt signaling and its nuclear translocation. In
addition to its dampening effects on active inflammation, EGCG has been shown to
actively

up-regulate

important

compensatory,

anti-inflammatory

pathways

simultaneously. Up-regulation of the anti-inflammatory cytokine TGF-β, as well as its
membrane receptors, has been reported in chondrocytes cultured with EGCG
(Andriamanalijaona, Kypriotou et al. 2005).

Additionally, EGCG administered to

endothelial cells downregulated the production of monocyte chemotactic protein (MCP)1 by activating the heme oxygenase-1 pathway, an important factor regulating cellular
responses to oxidative stress (Zheng, Toborek et al. 2010). Cellular proliferation and
survival signals evoked by the binding of IL-2 and IL-6 to their membrane receptors are
abrogated by EGCG, which simultaneously enhances compensatory pathways for
counterbalancing their pro-inflammatory effects. This compensation mechanism takes
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place by way of activation of suppressor of cytokine signaling (SOCS) proteins,
particularly SOCS1 (Ripley, Fujimoto et al. 2010).

SOCS1 protein dampens

inflammatory responses elicited by multiple activators of the immune system, such as the
binding of pro-inflammatory cytokines to their cognate receptors or bacteria-derived
peptides to the Toll-like membrane-bound receptor (TLR)-4. This action of SOCS1 is
attributable to direct interference with JAK kinase activation, as well as the enhancement
of JAK kinase degradation through the proteasome system (Yoshimura, Naka et al.
2007). Finally, SOCS1 also binds directly to an important co-factor in TLR-4 signaling,
MyD88-adaptor-like (MAL) protein. The direct binding of SOCS1 to activated MAL
accelerates proteasome degradation of this important factor linking TLR-4 signaling to
NF-κB activation (Mansell, Smith et al. 2006). In light of the important role these
intermediaries play in the immune activation cascade, which are central to the initiation
and maintenance of inflammation, it is not surprising that EGCG was able to effectively
subdue and control human ulcerative colitis.

The clinical manifestations of IBD are largely related to the indiscriminant effects
of cytokine release from activated immune cells. We have demonstrated that EGCG
effectively down-regulates the production of cytokines that are important in the
development of intestinal permeability. Mucosal immune activation results in part from a
loss of protection of the immune system from bacterial antigens, due to a breakdown of
the intestinal epithelial barrier (Sandle, Higgs et al. 1990, Braegger and MacDonald
1994). Although the initial instigator of barrier dysfunction remains a topic of debate,
clinical evidence demonstrates that prolonged exposure of the intestinal mucosa to high
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levels of Th1-type cytokines produces mucosal ulcerations in CD (Braegger and
MacDonald 1994). Therapies that reduce mucosal exposure to inflammatory cytokines
assist in healing the damage associated with IBD, ultimately re-establishing a protective
barrier that isolates the mucosal immune cell populations from exposure to antigenic
stimulation (Baert, D'Haens et al. 1999).

In this study, we established a general

protective role for EGCG in IBD through the reduction of cytokine production by the
major initiators of intestinal inflammation: the immune system and the epithelium. An
extensive body of data supports the notion that IL-1β, IFN-γ and TNF-α signaling,
through independent pathways, ultimately converge at the point of myosin light chain
kinase (MLCK) phosphorylation to enhance TJ permeability (Stow and Murray 2013).
However, the relative composition of TJ proteins occupying the TJ scaffold also
determines the functional state of the epithelial barrier. The pore-forming claudins (2, 7,
10, 15, and 16) and pore-sealing claudins (1, 4, 5, 8, 11, 14 and 19) (Krause, Winkler et
al. 2008) exist as preformed proteins which can be shuttled in or out of the TJ complex,
as influenced by external stimuli. Although the exact role played by many of these
claudins in IBD remains to be investigated, a recent study by Zeissig et al. found
downregulated expression of occludin as well as claudins 5 and 8 globally throughout the
mucosa of Crohn's patients with active disease, while claudin 2 was upregulated (Zeissig,
Bürgel et al. 2007). These changes in claudin expression were not exhibited during
periods of remission, suggesting that TJ remodeling and changes in claudin expression
occurred under the influence of cytokine mediators (Weber and Turner 2007). Along
these lines, Laukoetter et al. demonstrated that the increase in susceptibility to
experimentally induced colitis seen in JAM-A knockout animals correlated with
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increased expression of pore-forming claudins (10 and 15) that were present prior to
induction of the experimental injury (Laukoetter, Nava et al. 2007). Cytokine related
permeability changes have also been tied to cytokine signaling through TNFR2 (Shen,
Weber et al. 2011, Noda, Tanabe et al. 2012, Su, Nalle et al. 2013).
Based on the results from our experiments, it is evident that EGCG improves
barrier function. This is likely through two complementary pathways: by reducing
cytokine production from activated immune cells and their downstream effects on TJ
composition, as well as by directly influencing TJ protein composition. It is known that
epithelial cells regularly rotate claudins during normal junction maintenance and
homeostasis (Matsuda, Kubo et al. 2004). During periods of inflammation and NF-κB
activation, cytokine-dependent alterations in TJ constituent protein cycling patterns can
degrade barrier function by the substitution of pore-forming components integrated into
the TJ complex (Matsuda, Kubo et al. 2004). Elevated levels of claudin 2 have also been
documented in patients with acute colitis, and its presence correlates with increased
barrier permeability (Lu, Ding et al. 2013). This finding was corroborated in our results
with the increase in both claudins 2 and 4 when Caco2 cells were exposed to LPS.
Enhanced levels of these claudins correlated with decreases in the TER. However,
EGCG appears to have a direct effect on TJ permeability independent of cytokine
inhibition, as the addition of EGCG in the absence of LPS actually increased TER by
over 20%, while the level of TJ proteins remained essentially at baseline.

This

observation prompted additional experiments to determine the mechanism of this
observation. This effect of EGCG is likely tied to increased claudin 1 production, a
claudin that appears to exert tremendous influence on TJ resistance to ion flux. The data
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from WB and RT-PCR analysis of mRNA for claudin 1 supports the notion that EGCG
upregulates this important tightening claudin.

We are currently pursuing a novel

mechanism exploring the effects of HIF1α on CLDN1 promoter.

The data presented here demonstrate that the potent anti-inflammatory effects of
EGCG modulate the secretion of three cytokines (IL-1β, TNF- α and IFN-γ) by
circulating immune cells and intestinal epithelial cells. These three cytokines have been
shown to be integrally involved with inflammation-induced changes in epithelial tight
junction permeability. Examination of TER data presented in this paper clearly
demonstrates that EGCG increases epithelial electrical resistance and TJ protein
expression levels after 18-24 hours of incubation with Caco-2 cell monolayers. These
data suggest an additional mechanism underlying EGCG-mediated protection against
colitis (Azuma, Shigeshiro et al. 2013). Future studies on the anti-inflammatory effects
of EGCG should evaluate its impact on the regulation, expression, and function of barrier
related components in clinical subjects with IBD. These insights will provide critical
information for better understanding how EGCG impacts the molecular mechanisms
involved in inflammatory bowel disease, and guide the development of this potentially
beneficial therapeutic agent. Data binding EGCG’s anti-inflammatory and TJ regulatory
effects to the preservation of barrier function provides an explanation for the successful
treatment of ulcerative colitis documented in our clinical trial (Dryden, Lam et al. 2013).
These data and others provide justification for larger clinical trials to further evaluate the
impact of EGCG on the inflammatory pathways related to the IBDs, as well as confirm
its efficacy on the clinical manifestations of those disorders.
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